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Abstract 
Background Schizophrenia spectrum disorders are severe mental illnesses 
characterized by psychotic symptoms, cognitive dysfunction and functional decline. 
Cognitive impairments have been recognized as core features of schizophrenia, with 
great impact on functional outcome. Emerging evidence indicates involvement of 
immune system and inflammation in the pathophysiology of schizophrenia, and 
elevation of the inflammatory marker C-reactive protein (CRP) has been observed 
with association to pathogenesis and symptomatology including cognitive 
dysfunctions.                                                                                                             
Aims To investigate the association between CRP level and cognitive performance in 
both acute phase of psychosis (paper 1) and during a 6 month follow-up (paper 2), 
and study the differences between antipsychotics with regards to effect on CRP levels 
during a one year follow-up of schizophrenia spectrum disorders patients in acute 
phase psychosis (paper 3).                                                                                   
Methods Participants from the Bergen psychosis project study were assessed with 
measurement of the CRP level and cognitive assessments at baseline and first follow-
up visit at discharge/latest after 6 weeks (paper 1), in addition to cognitive 
assessments after 3 months and 6 months (paper 2). Patients from BestIntro study 
were assessed with measurement of CRP level at baseline, and after 1, 3, 6, 12, 26, 39 
and 52 weeks (paper 3).                                                                                                                  
Main results Inverse relationship between baseline CRP level and overall cognitive 
performance, delayed memory and attention were found. During the 6 month follow-
up global cognitive performance improved, and was associated with the initial CRP 
level reduction (paper1 and 2). Amisulpride, aripiprazole and olanzapine showed 
different effects on CRP levels, with a statistically significant increase in CRP levels 
during the first 1-3 weeks which lasted for 52 weeks for all groups. The aripiprazole 
group showed decrease in CRP level during the first week of treatment, and the 
change in CRP differed depending on whether or not the patient was antipsychotic-
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naïve (paper 3).                                                                                                        
Conclusions Findings support an inflammatory component to the cognitive 
impairment in schizophrenia spectrum disorders, which is partly state dependent. The 
CRP level changes in the acute phase of psychosis may predict cognitive function in 
later phases. Amisulpride, aripiprazole and olanzapine showed different effects on the 
immune system in acute phase psychosis, which might be both phase related and 
dependent on whether or not there was prior use of antipsychotics. All three 
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1. Introduction 
1.1 History of schizophrenia 
Schizophrenia spectrum disorders are severe and often chronic mental illnesses 
characterized by a heterogenic set of positive, negative, cognitive, mood, motor 
symptoms and functional decline with a lifetime prevalence close to 1% (1). The 
schizophrenia spectrum and other psychotic disorders according to The Diagnostic 
and Statistical Manual of Mental Disorders of American Psychiatric Association, 
Fifth edition (DSM- 5) introduces a conceptual psychosis continuum, where the 
differentiation between various forms of psychotic disorders is based on the level, 
number, and duration of psychotic signs and symptoms (2). Schizophrenia has been 
widely studied as a specific disease entity for the past century, but its precise nature, 
causes and pathogenesis remains unknown (3).  
In this thesis, the terminology of schizophrenia-spectrum disorders will therefore, be 
used as the common/modern definition for psychotic disorders including 
schizophrenia as the most studied disease entity in this spectrum.   
The history of schizophrenia as a disease entity dates back to the 19th century. 
Griesinger (4) described in 1891 conditions reflecting today’s chronic schizophrenia 
as a secondary development in a primary mood disorder and assumed a unitary 
psychosis disease entity. Hecker (5) described hebephrenia in 1871, a syndrome 
consisting of early onset of psychosis, affect and behavioural features, formal thought 
disorder, and a deteriorating course (5), followed by Kahlbaum’s clinical method 
developed in 1874, where psychiatric entities were based on the entire course of the 
illness consisting of prodromal phase, acute and outcome (6). In 1919 Kraepelin (7) 
recognized similarities between patients with catatonia, hebephrenia, and paranoid 
dementia regarding adolescent or early adult onset, deterioration tendency and an 
outcome of mental dullness or dementia, a group he called dementia praecox (1, 7, 8).   
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Bleuler (9) defined in 1919 a set of fundamental symptoms that he considered unique 
to schizophrenia. He considered delusions and hallucinations as accessory symptoms 
of schizophrenia, whereas the disintegration of different psychic functions, with 
fundamental symptoms of loosening of association, blunt or incongruous affect, 
ambivalence, and autism to be present in all patients, known as Bleuler's 4, and now 
considered as negative symptoms (1, 9, 10). 
 In 1946 Jaspers (11) proposed that impairment of empathic communication was the 
basic defect in schizophrenia (1, 11), followed by Schneider’s (12) high-valued 11 
first-rank symptoms in 1959, formerly considered as pathognomonic. These 
symptoms were audible thoughts, voices heard arguing, voices heard commenting on 
ones actions, the experiences of influences playing on the body (somatic passivity 
experiences), thought withdrawal and other interferences with thoughts, diffusion of 
thoughts, delusional perception, and all feelings, impulses (drives) and volitional acts 
that are experienced by the patient as the work, or influence of others, which are now 
considered as the positive symptoms of schizophrenia (12, 13). 
The further conceptualization, current definition, and diagnosis of schizophrenia are 
presented in next chapter. 
1.2 Clinical features and diagnosis 
Schizophrenia is essentially characterized by a set of signs and symptoms, including 
distortions of thinking and perception, cognitive impairments, motor symptoms, 
avolition and apathy, communication difficulties and limited affective expression. 
These abnormalities are classified in positive, negative, cognitive, disorganization, 
mood and motor symptom dimensions, which are expressed differentially among 





Positive symptoms are related to impaired reality testing and include delusions, 
hallucinations, and other reality distortions. Delusions of control, thought insertion, 
withdrawal and broadcasting, all from the Schneiderian first-rank symptoms have 
been traditionally linked to schizophrenia, but persecutory delusions and delusion of 
reference are most frequent (16). Hallucinations in all five sensory modalities can 
occur, however, auditory hallucinations are the most common. The reality distortion 
with positive symptoms marks the formal clinical onset of the illness. By using the 
Positive and Negative Syndrome Scale (PANSS) (17), (see below), a threshold for 
psychosis can be operationalized according to the scores for particular items (1, 18, 
19). 
Negative symptoms 
Negative symptoms are characterized by blunting or loss of a variety of affective 
functions, including dysfunctions in affective experiences and expression, abulia (loss 
of motivation), alogia (poverty of speech), anhedonia (inability to experience 
pleasure), avolition (lack of initiative), apathy (lack of interest), and reduced social 
drive (20, 21).   
Disorganization of thinking and behavior 
Disorganized thinking (formal thought disorders) is typically inferred from the 
individual’s speech. Patients may switch from one topic to another (derailment or 
loose associations), or answer to questions as obliquely related or completely 
unrelated (tangentiality). Rarely, speech may be so severely disorganized that is nearly 
incomprehensible (incoherence or ‘’word salad’’). Symptoms of disorganization have 




Mood and other symptoms 
Patients with schizophrenia frequently manifest mood symptoms, and may show 
increased emotional reactivity together with positive symptoms, called the emotional 
paradox (24). Significant depressive symptoms are seen in a majority of schizophrenia 
patients, can occur in any phase of the illness, and increase through an acute psychosis 
phase (25-27). 
Patients with schizophrenia may manifest other symptoms or clinical features such as 
psychomotor symptoms, (28, 29), the full-blown catatonic syndrome with stupor or 
excitement states, echolalia, echopraxia, automatic obedience, waxy flexibility, and 
extreme negativism (30), anxiety (31) and neurological deficits (32-35). Cognitive 
symptoms are discussed in greater detail due to the relevance for this thesis. 
  
Cognitive symptoms 
Kraepelin (7) described the disorder by using the term ‘’dementia praecox’’ that 
means literally cognitive decline with onset in youth. Positive symptoms have been 
considered as the most prominent features of the schizophrenia spectrum disorders for 
almost a century, but cognitive dysfunctions are recognized as core features of 
schizophrenia during the last decade (36-39). Cognitive symptoms have greater 
impact on functional outcome than the psychotic symptoms (40-46), and are present 
early in the disease course. While psychotic symptoms usually appear approximately 
in the age of 18-25 years old, cognitive deficits are observed much earlier in patients 
who develop schizophrenia (47). Children and adolescents who later develop 
schizophrenia show deficits in general cognitive abilities in terms of IQ and academic 
achievement (48-50), and specific premorbid impairments in a number of cognitive 
domains (51-53). It has been suggested that premorbid cognitive deficits support the 
neurodevelopmental model of schizophrenia, with mild abnormalities in cognitive 
development as the earliest signs of the illness (50, 54). Furthermore, cognitive 
dysfunction in schizophrenia is considered as signalling aberrant neurodevelopment 
during the first two decades of life (48, 49, 55). The presence of cognitive deficits 
years prior to the onset of psychotic symptoms suggests that cognitive dysfunction is 
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at the core of schizophrenia, with abnormal neurodevelopment manifesting through 
performative lag as early as preschool age (56). 
Moreover, robust impairments across multiple domains of cognitive functioning are 
highly prevalent, and observed in more than 80% of patients with schizophrenia-
spectrum disorders and can be detected in the premorbid phase of illness (39, 57). The 
cognitive impairments in schizophrenia are observed across all phases of illness and is 
predominantly generalized (58, 59), but also with additional impairments in specific 
domains of episodic memory, processing speed, verbal fluency, attention, executive 
functions and working memory. Literature reporting specific domain impairment 
show, however, mixed results (60) (61-68). 
Many studies have indicated that the cognitive impairments seem to stabilize after the 
first episode of psychosis (69, 70), although there have also been some findings 
suggesting cognitive improvements (71-75). 
A review of 163 publications of longitudinal studies of patients with schizophrenia 
(60) showed that cognitive impairment in first-episode schizophrenia patients is 
similar to the impairment seen in chronic stages. Moreover, a meta-analysis of 23 
studies of medication-naïve first-episode patients revealed medium to large effect 
sizes in all cognitive domains compared to healthy controls, with the largest 
impairment in verbal memory, processing speed, and working memory (76). These 
findings support the presence of significant cognitive impairment in the early stages 
of psychosis independent of antipsychotic medication use. 
1.2.2 Onset and course 
Schizophrenia is characterized by a sequential course consisting of premorbid- phase, 
prodromal phase, the first-episode psychosis (FEP), repeated episodes of psychosis, 
inter-episode remission, stable phase/plateau and recovery. More rarely, 





Significant numbers of investigations including birth-cohort observations have 
identified premorbid abnormal intellectual, social, affective, behavioral and academic 
functioning, in addition to delayed motor coordination development and abnormal 
motor functioning, and neurocognitive deficits (77).  
 
Prodromal phase 
The time preceding the first onset of psychosis has been described as the prodrome, 
and is characterized by subthreshold psychotic symptoms, in addition to a range of 
other clinical signs including cognitive deficits, negative symptoms, mood symptoms, 
and decline in function (47, 78). The duration of the prodromal phase varies from 
months to years, with a mean of approximately 5 years (79, 80). Psychotic 
experiences, ranging from mild attenuated experiences in healthy individuals to 
clinically full-blown psychosis in a few, have been suggested as continuum model of 
psychosis, with the ultrahigh risk for psychosis (UHR) close to the mild end (81, 82). 
One sixth to one-half of individuals, (depending on the population studied and criteria 
utilized) who seek treatment and meet the criteria for UHR develop schizophrenia 
(83-85).  
Onset, the initial psychotic episode and course of the illness 
For practical purposes, the development of frank psychotic symptoms defines the 
formal onset of the first episode of schizophrenia, consistent with Criterion A in the 
DSM-5 itemizing hallucinations, delusions, disorganized speech/ behavior, and 
negative symptoms. To meet this criterion, individuals should have two of these five 
symptoms for one month (or less if appropriately treated). International Statistical 
Classification of Diseases and Related Health Problems (ICD)- 10 uses a similar 
definition of schizophrenia.  
The onset of schizophrenia generally occurs at the age of 15-45 years, however, it can 
rarely debut before puberty or after the age of 50 years (86, 87). The first episode is 
typically initiated with an increase in mood and negative symptoms, considered as the 
prepsychotic phase, and followed by increasing positive symptoms until reaching a 
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peak, recognized as psychotic phase (88-90). The course of schizophrenia after the 
FEP varies across patients, characterized by exacerbations and remissions, with 
different degree of psychotic symptoms through the course of the illness. About 20% 
have only one episode. 
 
1.2.3. Comorbidities 
Patients with schizophrenia show increased rates of a range of comorbid medical and 
psychiatric diseases (91, 92). The prevalence of depressive disorder in schizophrenia 
has been reported to be around 40%, (27), and it is linked to poorer outcomes in 
schizophrenia (93). Other frequent comorbidities are anxiety and related disorders in 
schizophrenia (94).  
Furthermore, the prevalence of substance use (e.g., alcohol, cannabis, and cocaine) in 
patients with schizophrenia is as high as about 5 times of general population (95-97). 
Individuals with schizophrenia and substance abuse show higher rates of relapse, 
rehospitalization, violence, poor social functioning, medication non-adherence, worse 
clinical outcomes, and higher suicide risk (97, 98).  
 
Medical comorbidity 
Schizophrenia is associated with a substantially decreased life expectancy of 15–25 
years compared to the general population, with somatic diseases being a major cause 
for all these years of lost life (99). Smoking, low physical activity, obesity, 
hypertension, dyslipidemia, and elevated serum glucose levels are more common in 
individuals with schizophrenia than the general population (100-107). Atypical 
antipsychotics in addition to unhealthy life styles leading to dyslipidemia, 
hyperglycemia, and overweight, contribute to somatic comorbidities, including the 
metabolic syndrome and cardiovascular disease (108). However, a 4-years follow-up 
study of all individuals in Sweden with schizophrenia diagnoses found the highest 
overall mortality among patients with no antipsychotic exposure, compared with age- 
and gender-matched controls. The authors suggested that other factors than 
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antipsychotic use in adequate dosage might be involved in both excess overall and 
cardiovascular mortality in schizophrenia (109). Furthermore, increased risk for 
metabolic syndrome in drug-naïve patients and in first-degree relatives of 
schizophrenia patients (110), increased cardiovascular disease risk in young drug-
naïve patients with higher cholesterol levels, increased insulin resistance (111), and 
shared genetic risk for cardiovascular risk factors and psychotic disorders, indicate 
shared  pathophysiology independent of atypical antipsychotics among some of the 
patients (112). Individuals with schizophrenia have in addition increased risk for 
developing autoimmune diseases, infections, chronic obstructive pulmonary disease 
(COPD) and cancers (99). Smoking and poor health care and unhealthy life style 
might increase the risk of infections, COPD, some types of cancer, however, genetic 
link between schizophrenia and autoimmune diseases, cardiovascular disorders and 
type 2 diabetes have been suggested (113). The autoimmune comorbidity will be 
discussed more detailed in the pathophysiology section. 
 
1.2.4 Diagnosis and related aspects 
Since the pathophysiology of schizophrenia spectrum disorders has not been fully 
clarified yet, the diagnosis is according to ICD-10 and Diagnostic and Statistical 
Manual of Mental Disorders (DSM)-5 still based on symptom-related clinical criteria 
comprising certain psychopathologic features and the disease course (114, 115). The 
two major international diagnostic classification systems are developed by the World 
Health Organization (WHO) and the American Psychiatric Association (APA), 
respectively. WHO was entrusted with ICD in 1948 and published the 6th version, 
ICD-6. The ICD has been revised and published in a series of editions to reflect 
advances in health and medical science over time. It is the diagnostic classification 
standard for all clinical and research purposes.  
DSM is the other authoritative manual that defines and classifies mental disorders in 
order to improve diagnoses, treatment, and research.  
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The diagnoses broadly described as schizophrenia spectrum disorders according to 
ICD-10 diagnoses of F20-29 is considered as the non-affective pshychoses, separated 
from affective disorders (used in the inclusion process of the thesis projects), which 
are defined in the DSM-5 as schizophrenia (F20), schizophreniform disorder (F20.8), 
schizotypal disorder (F21), delusional disorder (F22), brief psychotic disorder (F23), 
and schizoaffective disorder (F25). The diagnostic category “Schizophrenia and other 
psychotic disorders” in the DSM-4 is changed to “Schizophrenia Spectrum and Other 
Psychotic Disorders” in the DSM-5 (116).      
1.3 Epidemiology 
A systematic review of the epidemiology of schizophrenia found median incidence 
(the number of new cases per given population per year) estimates of 15.2 per  
100 000, median lifetime prevalence (proportion of surviving individuals with a 
schizophrenia during a specified period) of 4.0 per 1000 and lifetime morbid risk 
(likelihood of developing schizophrenia during lifetime) 7.2 per 1000. Rates vary 
depending on the diagnostic definition of schizophrenia used (117). The evidence 
indicates that the incidence of schizophrenia is related to sex with a median male: 
female rate ratio of 1.4 (117, 118). Various risk factors for the development of 
schizophrenia have been identified. A meta-analysis of 38 studies compared different 
schizophrenia risk factors, suggesting 3 levels of risk (119). The highest risk factors 
are having a first-degree relative with schizophrenia (RR 6.99–9.31), or being the 
offspring of an immigrant from selected countries (RR 4.5). Intermediate risk factors 
include infection with Toxoplasma gondii (OR 2.73), being an immigrant from and to 
selected countries (RR 2.7), being born (RR 2.24) in or raised in (RR 2.75) an urban 
area, cannabis use OR 2.10–2.93), having minor physical anomalies (OR 2.23), or 
having a father 55 or older (OR 2.21). Low-risk factors include a history of traumatic 
brain injury (OR 1.65), sex abuse in childhood (OR 1.46), obstetrical complications 
(OR 1.29–1.38, having a father 45 or older (OR 1.38–1.66), specific genetic 
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polymorphisms (OR 1.09–1.24), birth seasonality (OR 1.07–1.95), maternal exposure 
to influenza (RR 1.05) (119).  
Stress mediated pathways have been suggested to be involved in some of the above- 
mentioned risk factors, such as migrant status, by social defeat/ethnic minority (117, 
120, 121), and urbanity by overcrowded stress in addition to environmental pollutants 
(122). Epidemiological studies of seasons of birth show an excess of winter births in 
individuals with schizophrenia in Northern hemisphere (123, 124), and with lower 
grade of excess in the Southern Hemisphere (123, 125, 126). Infections, temperature, 
length of photoperiod, nutritional factors and toxic factors have been suggested as 
potential mechanisms involved in seasonal variations of birth in schizophrenia (123, 
126, 127). As mentioned in a previous section a systematic review including 37 
studies showed a median standardized mortality ratio, all- cause of 2.6 for patients 
with schizophrenia which indicates a two- three fold increased risk of mortality 
compared to general population (McGrath, Saha et al. 2008). Suicide contributes to 
the increased mortality associated with schizophrenia (128). Besides, patients with 
schizophrenia have increased mortality risks due to comorbid somatic conditions 
(129).  
Maternal and childhood infections, childhood trauma, autoimmunity, together with 
the genetical aspects of the pathophysiology will be further discussed in details 
following the presentation of immunity and inflammation.  
1.4 Pathophysiology 
The pathophysiology of schizophrenia consists of both structural and functional 
aberrations. Schizophrenia is, however, characterized by a spectrum of 
neurobiological abnormalities which have been linked to putative etiological factors 
(130). This section will focus mainly on cross-talk between signalling and 
inflammatory aspects. 
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1.4.1  Neurotransmitter signaling     
Neurotransmitter systems in the brain, particularly dopamine have been the 
mainstream research focus regarding pathogenesis of schizophrenia (131). 
Dopamine 
The initiating source of the dopamine hypothesis of schizophrenia was based on 
studies on amphetamine and other substances with evidence of increase of 
extracellular concentrations of dopamine inducing psychotic symptoms similar to 
schizophrenia (132-134). Clinical studies showed furthermore, that the effectiveness 
of antipsychotic drugs was related to their affinity for dopamine receptors, suggesting 
abnormalities in dopamine receptor density leading to schizophrenia (135, 136).  
Evidence from positron emission tomography (PET) studies have shown reduced 
cerebral blood flow in the frontal cortex, suggesting regional brain dysfunction in 
schizophrenia. However, the term hypofrontality, originated from the low 
cerebrospinal fluid (CSF) dopamine metabolite levels, reflecting cortical dopamine 
metabolism, and was assumed to indicate reduced frontal dopamine levels (137). 
Schizophrenia was thus suggested to be characterized by frontal hypodopaminergia 
resulting in striatal hyperdopaminergia (137). Similarities between the behaviour of 
animals and humans with frontal lobe lesions and the negative symptoms of 
schizophrenia, suggest that the negative symptoms could be related to frontal 
hypodopaminergia. Positive symptoms are suggested to result from striatal 
hyperdopaminergia, since higher dopamine metabolite levels are found to be related 
to greater positive symptom load and response to antipsychotic drugs (138). 
Dopamine deficiency within dorsolateral prefrontal cortex leads to cognitive 
dysfunction. Both preclinical and clinical studies have shown relationships between 
prefrontal dopamine function and working memory, suggesting that insufficient D1 
receptor signaling in this area is involved in cognitive impairment (139). 
Furthermore, a meta-analysis of PET and single photon emission computed 
tomography (SPECT) imaging studies of dopaminergic function showed that 
presynaptic dopaminergic function (dopamine synthesis capacity, dopamine release 
 26 
and synaptic dopamine levels), dopamine transporter and dopamine receptor 
availability were altered in schizophrenia, but there was no difference in dopamine 
transporter availability (140). 
In the latest version of the dopamine hypothesis dopamine signalling is considered as 
the final common pathway to psychosis in schizophrenia, in which multiple factors 
interact resulting in dopamine dysregulation at the presynaptic dopaminergic control 
level (137). However, limitations of the dopamine hypothesis have been revealed 
during the last 20 years, and alternative models have been developed, including also a 
role for glutamate transmission and other systems (141).  
 
Glutamate 
Glutamate is the most abundant excitatory neurotransmiter in the brain. Glutamatergic 
neurotransmission is conducted through metabotropic and ionotropic  
Glutamate receptors, each subdivided in 3 groups. The ionotropic N-methyl-D- 
aspartate receptors (NMDAR) have particular relevance for psychosis, and will be in 
focus in this section. Glutamatergic pathways are linked to the cerebral cortex, limbic 
system, and the thalamus regions. There are increasing evidence of glutamate 
involvement in schizophrenia (142). Glutamatergic models were originally based on 
the observation of schizophrenia-like psychotic symptoms and neurocognitive deficits 
induced by the psychotomimetic agents such as phencyclidine (PCP) and ketamine by 
blocking neurotransmission at NMDAR (143, 144). NMDAR are located throughout 
the brain. Furthermore, NMDAR are located in brain circuits, which regulate 
dopamine release, indicating that dopaminergic deficits in schizophrenia might also 
be secondary to glutamatergic dysfunction (145). It has been suggested that dopamine 
has a modulatory effect on glutamate performance, and dopamine changes might thus 
affect NMDA activity (146). Furthermore, some of the products of brain 
inflammation, such as kynurenic acid (KYNA) and quinolenic acid bind to NMDAR, 





Other neurotransmitters such as serotonin (147), acetylcholine (148, 149), and 
Gamma-Aminobutyric Acid (GABA) (150-152) have also been suggested to be 
involved in the pathogenesis of schizophrenia, but further discussions are beyond the 
scope of this thesis. 
The above-mentioned multi-neurotransmitter models illustrate the neurochemical 
imbalances in various neurotransmitter systems involved in the pathophysiology of 
schizophrenia. Both etiological, epidemiological, and treatment challenges point to 
additional involved mechanisms. Antipsychotic drugs have mainly focused on 
dopaminergic antagonism at the D2 receptors, counteracting the hyperdopaminergia 
in nigrostriatal and mesolimbic systems. Current clinically available drugs effectively 
target the positive symptoms of psychosis such as hallucinations and delusions in the 
majority of first-episode patients, but show smaller effect sizes for negative symptoms 
and cognitive dysfunctions (153), indicating involvement of other pathophysiological 
mechanisms in addition to hyperdopaminergia. Interestingly, considerable cross-talk 
between neurotransmitter systems and inflammatory constituents exist in 
schizophrenia as will be further elaborated in the next section.  
1.4.2 Immunity and Inflammation 
The idea that inflammation might lead to psychosis started as early as the history of 
the schizophrenia syndrome, where Kraepelin (7) suggested that dementia praecox 
was caused by autointoxication from a focal somatic infection (154). Clinical 
observations of psychotic-, mood symptoms, and cognitive impairment often during 
or after an infectious condition together with discovery of Treponema pallidum in 
1905 as the aetiology of syphilis and associated psychosis, might have been the basic 
start of the inflammation theory (155). A potential role of inflammation in the 
pathogenesis of psychosis was introduced in 1918, by the observation of 200 reported 
cases of post-influenza psychosis, in which one-third had similar clinical 
manifestations as dementia praecox (156, 157).  
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In this section, immunity and inflammatory processes relevant to schizophrenia will 
be discussed. First, a general overview of the innate and adaptive immune systems 
will be presented. Next, cytokines involved in the immune response will be presented, 
leading to the final section elaborating on CRP, which is the main focus of this thesis. 
The human immune system has two different parts; the innate system (inborn), the 
oldest part and the first barrier with unspecific response to pathogens, and the 
adaptive system (acquired) which responds to specific antigens with long-lasting 
recognition (158, 159). The cells of the innate system are dendritic cells, 
macrophages, granulocytes, mast cells, and natural killer cells, and the humoral 
responses of the innate system consist of the complement system, cytokines, 
interferons and extracellular enzymes. The cells of the adaptive system are the B- and 
T lymphocytes, and the antibodies are the humoral part of the adaptive system. As a 
response of the innate system to microorganisms, physical stress, aseptic tissue injury 
or ischemia, an inflammatory process develops (158). Toll-like receptors (TLRs) 
located at the macrophages have an essential role in inducing phagocytosis and 
production of albumin, fibrinogen, serum amyloid A protein and CRP, all as acute 
phase proteins (160). An acute response may in addition lead to cytokine production, 
which stimulates B- and T lymphocytes to create antigen specific responses. In an 
adaptive response, contact with a specific antigen (protein or polysaccharide part of 
pathogen) stimulates naïve T cells to proliferate and differentiate into decision-
making effector cells.  
Moreover, the evidence suggests cellular activation of microglia particularly in the 
hippocampus and whole-brain gray matter in individuals with schizophrenia (161, 
162). Disturbances of other immune cells are also identified in patients with 
schizophrenia, but are considered beyond the scope of this thesis.  
1.4.2.1 Cytokines 
Cytokines are low-molecular weight proteins produced and secreted by different 
immune cells and other cells in response to environmental triggers, and play an 
essential role in early host defense against microorganisms. The innate immunity is 
 29 
mediated by cytokines by inducing protective local inflammation and systemic acute 
phase responses. Cytokines are also involved in initiating, amplifying, mediating, and 
regulating adaptive immunity, and can cause tissue damage under excessive responses 
or autoimmunity (163-166). Furthermore, cytokines show effects on the recruitment 
and activation of lymphocytes, in addition to the control of immune cell 
differentiation and homeostasis. Some cytokines induce cell apoptosis and inhibition 
of protein synthesis by direct effector mechanisms. They bind to specific receptors on 
the membrane of target cells, trigger signal transduction pathways and subsequently 
alter gene expression in the target cells. Cytokines are grouped according to their 
main production sites and functions in the peripheral immune system. Cytokines 
Interlukin (IL)-1ß, IL-6, IL-2, IL-12, Interferon (IFN)-γ, and tumor necrosis factor 
(TNF)-α are often classified as pro-inflammatory cytokines due to their roles in the 
early defense against infection and the initiation and/or progression of inflammatory 
processes. IL-10, IL-4 and transforming growth factor (TGF)-ß are considered as anti-
inflammatory cytokines, and limit both production and activity of many pro-
inflammatory cytokines (167, 168). However, this dual categorization  is questioned, 
since some of the cytokines pose both properties depending on the context (169). 
Cytokines and their receptors are expressed by glial and neuronal cell types in the 
adult central nervous system (CNS) (170). The fact that many cytokines and their 
receptors are constitutively expressed during fetal brain development in humans, 
might suggest their roles in the regulation of brain development (171). Therefore 
abnormal levels of cytokines during early brain development theoretically might 
influence neurodevelopmental processes with susceptibility for different complex 
brain disorders like schizophrenia (172).  
Several reviews and meta-analysis studies have revealed alterations in cytokine levels 
in patients with schizophrenia (173, 174). Increased levels of the IL-1Ra, sIL-2R, IL-
6 (175), increase in IL-1 β, IL-6 and TGF-β during acute exacerbations and FEP 
(176), increased levels of IL-1b, sIL-2R, IL-6, and TNF-a in drug-naive FEP (177), 
and elevation of IL-6, TNF-α, IL-1Ra, and sIL-2R in acute episodes (178) are some of 
the findings.  
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Furthermore, negative associations between pro-inflammatory cytokine levels, such as 
IL-2, IFN-γ, and TNF-α and prefrontal cortical thickness in individuals at risk of 
psychosis who develop a psychotic disorder (179) support the potential role of 
cytokines in the pathophysiology of psychotic disorders.  
IL-1, IL-6 and TNF-α are considered to have major roles in the immune dysregulation 
pathway of schizophrenia, interact with CRP, and are reviewed in detail in the 
following. 
IL-1 with its role in the differentiation and function of lymphoid cells is a central 
mediator of innate immunity and inflammation. It is mainly produced by activated 
macrophages, activated by for instance IFN- γ and bacterial products. The IL-1 family 
includes predominantly pro-inflammatory cytokines IL-1α, IL-β, IL-18, IL-33, IL-
36α, IL36-β, IL36-γ, IL-1Ra, IL-36Ra, IL-38 and one anti-inflammatory cytokine IL-
37. All cells of the innate immune system are affected by IL-1 family members. 
Binding of IL-1 initiates and strengthens the acute phase response by inducing fever, 
which in turn increases migration of leucocytes, by stimulating the acute phase 
proteins such as CRP, by activation of the hypothalamus-pituitary-adrenal (HPA) axis 
with cortisol regulating, and by inducing adhesion molecules with increase in 
leucocyte recruitment (158, 180). 
 IL-6 is produced by immune cells, adipocytes, skeletal muscle cells and endothelial 
cells, and the IL- 6 receptor (IL-6R) is located on macrophages, lymphocytes, 
neutrophils and hepatocytes. IL-6R exists in a soluble form (s); sIL-6R with 
circulating IL-6/sIL-6R complex.  SIL-6R is formed by proteolytic shedding mostly 
from the surface of neutrophils and monocytes (181). The shedding process is 
stimulated by several factors including CRP (through this mechanism amplifies the 
IL-6 signaling), and IL-8 (182-184). In acute inflammation, IL-6 stimulates the 
expansion and activation of T cells and differentiation of B cells, and modulates the 
synthesis of acute phase reactants such as CRP, fibrinogen and albumin (185-188). 
Furthermore, other manifestations of acute inflammation, such as fever, activation of 
the HPA axis, anorexia, and lethargy are induced by IL-6 (185).  
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TNF-α is another pro-inflammatory cytokine with important functions in innate and 
adaptive immunity, cell proliferation and apoptotic processes. It is produced in 
macrophages, monocytes, T cells, adipocytes, fibroblasts and smooth muscle cells, 
with binding to TNF-RI and TNF-RII. These receptors are located on all human body 
cells except erythrocytes (189).TNF- α together with IL-6 and IL-1ß stimulate the 
CRP production (190, 191). Moreover, chronic inflammation is a common risk 
pathway for cardiovascular diseases and type 2 diabetes frequently observed in 
schizophrenia (190).  
Taken together, evidence on alterations in cytokines level- and expression with 
normalization after treatment, and correlations between elevations in some of these 
cytokines and brain structure suggest that at least some of the cytokines may 
contribute to the pathophysiology in schizophrenia. 
1.4.2.2 CRP 
CRP is a protein synthesized in the liver, and was originally discovered in 1930 (192), 
due to the identification of a substance in the serum of patients with acute 
inflammation reacting with antibody against the carbohydrate (C) of the 
pneumococcus capsule. Hepatocytes are responsible for the synthesis of blood CRP 
(Gabay and Kushner, 1999), however, in obese individuals CRP is probably also 
produced by adipocytes leading to an increase in CRP (193, 194). CRP has a role in 
the innate immune system, and activates the complement cascade by binding to the 
surface of microbes or elements released from damaged cells (195). CRP as an acute-
phase reactant with its well-established range interval has been considered as a 
reliable marker of inflammation for many decades (196). 
There are several causes of increased CRP levels including acute and chronic states of 
infectious or non-infectious conditions, such as tissue and cell damage due to trauma. 
CRP is mainly induced by the IL-6 action on the gene responsible for transcription of 
CRP during the acute phase of an inflammatory or infectious process (197-199). 
However, IL-1, glucocorticoids and complement activation products, act in parallel 
with IL-6 and enhance its effect (199).  
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In daily clinical practice, a blood specimen is taken from a peripheral vein, and 
fasting is not required before the blood draw. The used high-sensitivity (hs)-CRP is 
usually reported in mg/L, allows a lower detection limit of 0.1mg/L (196, 200).  
Certain medications, such as non-steroidal anti-inflammatory drugs (NSAIDs) will 
decrease CRP levels, however some studies show no association between for instance 
low dose aspirin use and CRP levels (201-203). The decreased CRP levels occur with 
both NSAIDs and statins by reduction in inflammatory response. Magnesium 
supplementation can also decrease CRP levels among individuals with CRP >3mg /L 
(204).  
The level of CRP in healthy persons are generally considered to be < 3mg/L. CRP 
levels in the 3-10 mg/L range suggest low-grade inflammation, while CRP levels 
>10mg/L may suggest an inflammatory condition (205), and might be associated with 
infection in about 80% of cases (206). Moreover, elevations in CRP levels are 
associated with different factors including age, body mass index and smoking (207-
210). Several studies have, however, reported marginal variations in the level of CRP 
related to age, gender and ethnicity (211-214). Minor CRP elevations are shown in 
individuals with low socio- economic status which might be attributed to the higher 
prevalence of infections and diseases (215), and poor dietary supply of nutrients in 
this group (208). CRP is also considered as a risk marker for cardiovascular events, 
with a threshold of CRP ≥ 2 to indicate increased cardiovascular risk (216) in the 
general population, and for mortality related to vascular and non-vascular diseases, 
several cancers and lung disease (217). 
 
CRP and mental disorders 
The association between the level of CRP and different mental disorders has been 
investigated for decades (218-226). The association between CRP and schizophrenia 
has been studied both with regards to its putative role in the pathogenesis and in 
relation to the symptomatology (227). In schizophrenia, elevated serum levels of CRP 
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have been found in some studies (228, 229), and the results from 2 meta-analysis are 
presented here.  
A meta-analyses including 85 000 participants from 26 studies of CRP levels in 
individuals with schizophrenia showed moderately increased CRP levels regardless of 
the use of antipsychotics. The extent of the increase in CRP levels was associated 
with the severity of positive symptoms, and BMI (230). Another meta-analysis 
showed moderately increased level of CRP in individuals with schizophrenia, 
irrespective of study region, sample size of included studies, patient mean age, age of 
onset and BMI (227). Moreover, associations between elevated serum levels of CRP 
and more severe psychopathology (228, 231), treatment resistance (232), negative 
symptoms (233, 234), positive symptoms (234), depressive symptoms (235) and 
cognition (236, 237) have been found. 
Moreover, a large genome-wide association (GWAS) study (238) and also a 2-Sample 
Mendelian Randomization Study (239) showed a preventive effect of genetically 
elevated levels of CRP on schizophrenia risk. The authors from the latter study 
speculated that the blockade of IL-6 signalling, and lower levels of CRP might 
increase susceptibility to early life infection, with possible increased risk of 
schizophrenia.  
 
1.4.2.3 Neuroinflammatory signalling 
There is evidence for various CRP related alterations in the CNS, such as associations 
between elevated CRP levels- and cerebral microstructural disintegration (240), 
blood-brain barrier permeability (241), white matter pathology (242), and reduced 
cortical thickness in frontal, insula, and temporal brain regions (237). Moreover, 
cytokines alterations have been suggested to be involved in neuroinflammatory 
processes, examples are the findings of a role for IL-6 and TNF-α in activating the 
hypothalamic–pituitary–adrenocortical axis (243, 244). Brain imaging studies have 
been conducted to demonstrate neuroinflammatory signaling, including PET, 
Magnetic resonance imaging (MRI) spectroscopy, diffusion tensor imaging (DTI). 
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Associations between DTI measures and the levels of IL-6 and CRP suggest the 
contribution of IL-6 and CRP to impaired anisotropy of water diffusion in immune 
related neural pathways (245). To what extent findings of a pro-inflammatory state in 
peripheral blood reflect brain inflammation needs to be clarified. The interactions 
between inflammatory markers and neurotransmitters might, however, shed light on 
the neuroinflammatory pathways. There is evidence on interactions between 
interleukins and neurotransmitter systems in schizophrenia (Figure 1), revealing an 
important role of at least two interleukins. IL-1β induces rat mesencephalic progenitor 
cells to be converted into a dopaminergic phenotype, and IL-6 decreases the survival 




Figure 1.Simplified putative interplay between selected neurotransmitters, oligodendrocytes, 
and inflammation in the pathology of cognitive dysfunctions in schizophrenia. 
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GLU = excitatory pyramidal glutamatergic neuron, GABA = inhibitory GABAergic 
interneuron, D = dopaminergic neuron, O = oligodendrocyte with white myelin sheets 
enclosing the pyramidal cell axon, KYNA = kynurenic acid, QUIN = quinolinic acid. 
Adapted from (153) with permission. 
 
Evidence from viral-like infection models in animal studies have shown increase in 
the number of mesencephalic dopaminergic neurons in the fetus brains (248), and 
association between chronic administration of IF-α and reduction in striatal dopamine 
release (249). These findings point to various effects of inflammation on 
dopaminergic neurotransmission in schizophrenia. Moreover, glutamate is involved in 
cytokine directed tryptophan-kynurenine metabolism, mediated via NMDAR (250-
252). KYNA as the only known naturally occurring NMDAR antagonist in the human 
CNS is one of the intermediate neuroactive products in the kynurenine pathway (253). 
It is suggested that the immune response might inhibit indoleamine 2,3-dioxygenase 
(IDO), resulting in increased production of  KYNA, with consequent antagonism at 
NMDAR and a lack of glutamate neurotransmission (254, 255).  
 
1.4.2.4 Genetical aspects of immunity and inflammation in 
schizophrenia 
GWAS have revealed a multitude of genetic risk variants with low effect (256), which  
indicates that environmental factors interacting with the genetic background 
contribute to the pathophysiology of schizophrenia (257). Findings from GWAS 
estimated that in schizophrenia about 8.300 single nucleotide polymorphisms (SNP)s 
contribute to a common risk of 32% (258). Furthermore, one of the largest 
schizophrenia GWAS conducted by the Schizophrenia Working group of the 
Psychiatric Genomics Consortium, including a total of 36,989 schizophrenia cases 
and 113,075 controls, has identified 128 independent genome-wide significant 
associations spanning 108 loci. The fact that associations were enriched among genes 
expressed in tissues that play important roles in immunity, independent of gene 
expression in brain, supports the hypothesized link between the immune system and 
schizophrenia (113). Significant association with several markers spanning the major 
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histocompatibility complex (MHC) region on chromosome 6 is consistent with an 
immune component to schizophrenia risk (131).   
Moreover, findings from Danish national registers showed that a history of any 
autoimmune disease was associated with a 45% increase in risk for schizophrenia, 
that might indicate direct involvement of human leucocyte antigens (HLA) or physical 
closeness between loci for the autoimmune disorders and schizophrenia in HLA 
regions (259), which might support the correlation between immune responses and 
disease risk (260).  
 
1.4.2.5 Environmental risk factors 
Schizophrenia as a complex disorder is caused by both genetic and environmental 
factors and their interactions. Twin studies show a heritability of about 60– 80% in 
schizophrenia (261), which is higher than non-twin, with  estimates ranging from 64% 
to 47.3% (262, 263). Different environmental factors in addition to a strong genetic 
contribution (264) seems to increase the risk of schizophrenia and other psychoses 
(265). Some of the following environmental factors are mentioned in the section of 
epidemiology, and are further discussed here due to their inflammatory aspects. 
Environmental factors are proposed to explain up to 60% of the risk (Benros et al., 
2011). Factors involve prenatal or postnatal phases critical for CNS development, via 
a primary cerebral insult or pathological process long before the clinical manifestation 
of the illness (266-273). Perinatal factors including maternal infections, hypoxia, 
stress and malnutrition are, however, relevant for a small proportion of schizophrenia 
cases (114, 274-277).  
Maternal infections 
Several epidemiological studies have demonstrated an increased risk for 
schizophrenia in offspring of mothers exposed to influenza (278-280), although a 
meta-analysis found the validity of the serological studies related to the pandemic 
in1957 to be limited, due to high risk of misclassification of timing of exposure (281). 
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Infections with other viruses such as rubella, measles, varicella-zoster, polio, 
cytomegalovirus, and herpes simplex virus type 2, in addition to parasites such as 
Toxoplasma gondii, and genital/reproductive infections are associated with an 
increased risk of schizophrenia (119, 282-289). Furthermore a systematic review of 
prenatal maternal infection indicates that such infections with any of a number of 
pathogens are associated with the risk of schizophrenia –related psychosis in adult 
offspring (290). 
Interestingly, associations between increased maternal serum levels of inflammatory 
markers such as CRP (291), pro-inflammatory cytokines IL-8 and TNF-α with 
increased risk of schizophrenia have been shown (292, 293). Moreover, elevated 
maternal anti-inflammatory cytokines; IL-4, IL-5 and IL-13 in pregnancy were 
associated with decreased risk of schizophrenia (294). It has been suggested that the 
induction of pro-inflammatory cytokines by the maternal immune system might have 
implications on altering early brain development, which can increase the risk of 
schizophrenia and related disorders (172, 295, 296). Furthermore, there is evidence 
for the association between obstetric complications and early-onset schizophrenia, 
which might indicate the involvement of neurodevelopmental impairment (275, 297, 
298). Hypoxia is suggested as a possible mechanism between some of perinatal 
abnormalities and schizophrenia (299). Fetal hypoxia might lead to neuronal death, 
white matter damage with impaired myelination and reduced growth of dendrites 
(300). Hypoxia suppresses glutamate transport in astrocytes and therefore promotes 
extracellular accumulation of glutamate (301). Excess of glutamate might damage 
oligodendroglia and myelin with effects on oligodendrocyte differentiation, resulting 
in synaptic imbalance between axons and oligodendroglia, and dysfunction of the 
glial network of oligodendrocytes and astrocytes (302, 303). Furthermore, activation 
of microglia by hypoxic periods might mediate cell damage through nitric oxide 
synthase production, which links neonatal hypoxia to inflammatory processes (304).  
To summarize, evidence indicate that in susceptible individuals, genetic and 
environmental factors might interact with abnormal cytokine signaling, myelin 
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damage and glial changes leading to abnormal in utero and early postnatal 
neurodevelopment. Thus, inflammation might act as a potential common mediator of 
other known prenatal and perinatal risk factors for schizophrenia (305). 
Childhood infections 
Childhood CNS infection have been associated with increased risks of subclinical 
psychotic symptoms in adolescence and schizophrenia later in adult life (292, 306-
311). Furthermore, in a follow-up study of male participants with two or more 
hospitalizations for infections before the age of three, an 80% higher risk of 
schizophrenia were observed (312). 
In a meta-analysis, a longitudinal association between higher serum CRP levels in 
adolescence and subsequent schizophrenia, as well as earlier age of onset have been 
shown (313). The immune response phenomenon of kindling, have been suggested as 
a possible mechanism, in which, an initial immune response to a stimulus, for 
instance stress or infection, strengthens the response and/or lowers the threshold for a 
response to future exposure to the same stimulus (314). This hypothesis supports the 
increased vulnerability or schizophrenia by stimulation of an inflammatory response 
both in the mothers in the second trimester or in the offspring, during the CNS 
developing phase. In the CNS, stress may cause activation and proliferation of 
microglia, which in turn may mediate the cytokine effects (315). Pro-inflammatory 




Several studies have identified higher frequency of childhood maltreatment in patients 
with severe mental disorders including schizophrenia (318-320). Findings from a 
study of childhood trauma which compared patients with schizophrenia spectrum 
disorders and substance abuse showed that 64.9 % of patients from both groups were 
exposed to childhood trauma (321). Elevated emotional reactivity to stress,  
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alterations in the HPA axis, or augmentation of the effect of childhood trauma due to 
have been proposed as involved mechanisms (322-324). With regards to 
inflammation, findings from FEP studies show that only cases exposed to childhood 
trauma demonstrated higher levels of CRP (318) and TNF-α- (325) compared with a 
healthy control group. In a study of individuals with psychosis spectrum disorder with 
a diagnosis of schizophrenia or bipolar disorder, elevated CRP levels and higher BMI 
levels were found in both groups, and the level was also associated with the number 
of abuse types, emotional, physical or sexual abuse (319). The authors suggested that 
trauma-related immune activation and CRP elevation in patients with schizophrenia 
and bipolar disorders could be mediated by higher BMI, but the direction of this 
relationship needs to be clarified. 
In a recent study of patients with schizophrenia/schizoaffective or psychotic bipolar 
disorders pro-inflammatory cytokines IL-6, TNF- α and CRP were higher only in the 
schizophrenia group compared with healthy controls, and CRP levels were positively 
associated with sexual abuse only in the schizophrenia group (320). Associations 
between increased pro-inflammatory cytokines and CRP levels, and childhood trauma 
in schizophrenia, might thus suggest the role of early trauma exposure on activation 
of immune system. 
 
Autoimmunity 
Associations between autoimmune disorders and schizophrenia has been shown 
repeatedly, and recent studies suggest an autoimmune model for schizophrenia (326). 
Findings from birth registry studies have shown positive association between a range 
of autoimmune related disorders such as multiple sclerosis, systemic lupus 
erythematosus, autoimmune thyrotoxicosis, autoimmune hepatitis, psoriasis and 
diagnosis of schizophrenia or psychosis (259, 327-330). However, an inverse 
correlation in prevalence between rheumatoid arthritis and schizophrenia has been 
documented (328, 331-333). In a Danish cohort study a significant relationship 
between autoimmune disease, the number of severe infections, and the risk of 
schizophrenia were found, that might suggest a common pathogenic mechanism 
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(334). Moreover, a history of an infection, and exposure to anti-infective agents such 
as antibiotics, as well as having a family member with schizophrenia elevated 
significantly the risk for developing an autoimmune disease (327, 335). Interestingly, 
it is suggested that a contemporary inflammatory process associated with autoimmune 
disease and/or infection might affect the brain through increased permeability of the 
blood-brain barrier mediated by autoantibodies and cytokines (336). Autoimmune 
encephalitis with psychotic symptoms is considered as a disease entity of organic 
psychosis with autoantibodies against synaptic and neuronal cell surface antigens such 
as NMDAR (115, 337, 338). 
To summarize, the causes of schizophrenia are not fully clarified yet, but evidence 
from several studies suggest that the disorder might be a product of gene and 
environmental factors interacting during critical neurodevelopmental time points 
(113, 339-342). The very elegant summarizing message (326) should be adapted as 
whole; Studies in schizophrenia reveal an intricate association of environmentally-
driven immune activation in concert with a disrupted genetic template.  
1.5  Treatment of schizophrenia  
Management of patients with schizophrenia consist of various therapeutic approaches 
including pharmacological treatments, psychologic interventions, especially cognitive 
behaviour therapy (343, 344), family interventions (344-346), work/employment 
supports (347), social- and life skills training (344, 348), and cognitive enhancement 
programs (349, 350). Exercise interventions are shown to improve both the 
psychiatric and comorbid somatic conditions (351). Moreover, a review of studies on 
music therapy showed that music therapy used as add-on to standard treatment might 
improve negative and general symptoms, as well as quality of life in patients with 
schizophrenia (352). In a meta-analysis a better treatment effect was shown in the 
patients who received adjunct music therapy regarding negative symptoms, mood 
symptoms, and positive symptoms (353). Finally, the treatment of comorbid somatic 
condition is an essential part of the management of patients with schizophrenia (354).  
 41 
Furthermore, over the past two decades there has been increasing interest in 
psychological and pharmacological interventions to prevent or delay the transition of 
the prodromal state to florid psychosis, with mixed results (355-360). Such 
interventions can in addition, treat current co‐morbidities such as depressive or 
anxiety symptoms, and might improve outcome in individuals at risk for psychosis. 
With already engaged treatment, in case of transition to psychosis, the duration of 
untreated psychosis can be minimized, and might improve outcome (356, 357).  
1.5.1 Antipsychotic drugs 
The discovery of chlorpromazine in the 1950s (361-363) and development of 
clozapine in 1958 (364) are considered as two major milestones in the 
pharmacological treatment of schizophrenia (365). The first antipsychotic drugs 
developed in the 1950s and 1960s were characterized by dopamine D2 receptor 
antagonisms of varying potency among the different agents, and are nowadays 
generally classified as first generation antipsychotics (FGA) or typical antipsychotic 
drugs. FGAs such as haloperidol and perphenazine are all targeting the striatal 
hyperdopaminergia, and the main mechanisms of action are related to their D2 
receptor antagonism (136). The side effect profiles of the FGAs include 
extrapyramidal symptoms (EPS), and the emergence of EPS was for a long time 
considered necessary for their antipsychotic efficacy. This dogma was challenged by a 
group of German researchers, who subsequently demonstrated the efficacy of 
clozapine, an agent that had the “atypical” characteristic of being a very efficacious 
antipsychotic drug despite very low propensity for inducing EPS (364). Despite the 
association of striatal dopamine blockade with the risk of EPS, it is important to note 
that this is not the critical site of action for therapeutic effect, which occurs most 
prominently in the mesolimbic brain system (366). During the past five decades 
several FGA and later second generation antipsychotics (SGA)s have been developed, 
which all block D2 striatal receptors (367). The SGAs are pharmacologically 
characterized by relatively weaker affinity for the D2 receptor compared to the FGAs, 
and a strong affinity for the serotonergic 5 hydroxytryptamine 2A (HT2A) receptor 
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(368, 369). An exception to this general rule concerns amisulpride, which despite 
having an “atypical” profile clinically, only targets the dopaminergic system with 
high-affinity and highly selective D2/D3 receptor antagonism (370). It is suggested 
that its selective affinity for dopamine receptors in the limbic structures, but not in the 
striatum, leads to a low risk of extrapyramidal side effects (371). Furthermore, it has 
been suggested that in low doses it preferentially blocks presynaptic dopamine 
autoreceptors, which facilitates dopaminergic transmission with effects on negative 
symptoms (372).  
Aripiprazole is distinguished from other antipsychotics by its partial agonist activity at 
D2, D3, 5-HT1A, and 5-HT2C receptor targets (373-375).  In vitro, aripiprazole is a 
neutral antagonist or very weak partial agonist at 5-HT2A and 5-HT7, and is an 
inverse agonist at 5-HT2B receptors (374). As a D2 receptor partial agonist with 
moderate intrinsic activity, aripiprazole might functionally antagonize transmission at 
postsynaptic D2 receptors in neural systems with high dopaminergic tone, as in the 
striatal dopamine system of schizophrenic patients, which may account for its effects 
on positive symptoms. Oppositely, it may activate postsynaptic D2 receptors in neural 
systems with low dopaminergic tone, as in the mesocortical system, which may 
account for its putative effects on negative and cognitive symptoms in patients with 
schizophrenia. Besides partial agonist activity at D2 receptors, aripiprazole’s agonist 
activity at 5-HT1A receptors, from partial to full agonist depending on the cellular 
system, may also contribute to its efficacy and reduced side effects, relative to FGAs. 
Aripiprazole activates 5-HT1A receptors, reducing serotonin release and subsequently 
increasing dopamine release in the cortex, which might improve  negative and 
cognitive symptoms of schizophrenia (376). Relative to other SGAs, such as 
clozapine and olanzapine, aripiprazole has a lower weight gain-inducing propensity 
(377), as SGAs are potent 5-HT2C and H1 antagonists or inverse agonists 
contributing to their tendency to induce weight gain (377). Aripiprazole is conversely  
a partial agonist at the 5-HT2C receptor, similar to lorcaserin, an effective weight 
reducing agent with selective 5-HT2C agonism (377). Aripiprazole with its different 
dopamine receptor-binding profile is sometimes referred to as a third-generation 
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antipsychotic, and its stabilizing function leads to symptoms improvement and lower 
potential  for EPS, sedation, and hyperprolactinemia compared to other antipsychotics 
(378). 
There are, however, some limitations to the dopamine hypothesis in schizophrenia.  
Current antipsychotics are mainly effective against positive symptoms, while they are 
less effective against negative symptoms and cognitive dysfunctions (153, 379). The 
fact that clozapine shows a unique therapeutic efficacy in many of non-responder 
patients despite low affinity for/occupancy at D2 receptors, questions the D2 
receptor’s role as a global phenomenon in all patients with psychosis (137, 380).   
Furthermore, current treatments in psychosis, including psychosocial interventions 
and antipsychotic medications, have few if any beneficial effects on cognitive 
performance (153, 381-386). There are, however, findings of significant 
improvements in cognition in early-psychosis patients, using atypical or typical 
antipsychotics (384, 387), together with meta-analysis findings of no global 
differences in cognition for typical versus atypical anti-psychotics (385).  
1.5.2 Pro-cognitive effects of antipsychotic drugs 
Effect of antipsychotics on cognition has been widely studied (71-74). In a 
randomized double-blind treatment trial including 817 schizophrenia patients, who 
received one of the following antipsychotics olanzapine, perphenazine, quetiapine, 
risperidone, and ziprasidone a small but significant improvement in cognitive ability 
in all cognitive domains, and with all of the antipsychotics were found after two 
months (388). A follow-up study of first-episode schizophrenia spectrum disorders 
with follow-up intervals of 1-year and 3-years showed improvement of the cognitive 
performance in all domains (70). Another longitudinal study demonstrated 
improvement of general cognitive function, working memory, and verbal learning 
after 12 weeks, but these changes were mediated by improvements in both positive 
and negative symptoms (389). 
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To summarize, current antipsychotic treatment options in patients with schizophrenia 
have small beneficial effects on cognitive performance (153, 381-385). 
1.5.3 Anti-inflammatory effects of antipsychotic drugs 
The immune modulatory effects of antipsychotics have been studied, also with 
regards to the impact on levels of inflammatory markers, however, with mixed results. 
General effects on inflammation  
There have been several studies including patients with schizophrenia in order to 
clarify the effects of SGAs on the levels of inflammatory markers such as CRP and 
cytokines (230, 390-394).  
With regards to effects of antipsychotics on cytokines, the results are mixed. Meta-
analyses and other studies of the antipsychotics have revealed both anti- and pro-
inflammatory effects by alterations in the levels of IL-1β, IFN-γ, IL-6, TGF- β, IL-1b, 
TNF-α, IFN- γ, IL-12, IL-23, IL-1RA, sTNF-R1, IL-10, IL-4, and IL-2 (176, 391, 
395-398). 
Effects on CRP 
There are several studies with a focus on CRP levels in patients with schizophrenia, 
and the results are mixed. A meta-analysis of 26 studies including 85 000 participants 
showed moderately increased CRP levels in schizophrenia regardless of the use of 
antipsychotics, and with not significant changes between the first episode of 
psychosis and progression of the illness (230). Findings from a study of the effects of 
the antipsychotics olanzapine, risperidone, ziprazidone, quetiapine and perphenazine 
on CRP levels showed that olanzapine and quetiapine had the highest median levels 
for CRP after 3 months treatment (393). The 18-month repeated measures CRP 
analysis confirmed significantly higher values for olanzapine in those with low 
baseline CRP (393). In a recent study aripiprazole was the only antipsychotic drug 
associated with decreased CRP levels compared to the other antipsychotics; 
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quetiapine, olanzapine, amisulpride, clozapine, loxapine, risperidone zuclopenthixol, 
paliperidone, and cyamemazine (399). Findings from a study of patients with 
schizophrenia consisting of 67 antipsychotic medicated and 28 psychotropic 
medication-free schizophrenia patients showed a significantly higher level of CRP 
and IL-6 among the antipsychotic medicated patients(400). In a 4- weeks follow-up 
study of 17 chronic schizophrenia patients, previously medicated with typical or 
atypical oral antipsychotics (haloperidol, perazine, zuclopenthixol, perphenazine, 
ziprazidone, risperidone, quetiapine, olanzapine, and amisulpride) switching to 
aripiprazole showed a significant reduction in CRP level (391). Taken together the 
results from studies regarding the effects of antipsychotics on the levels of 
inflammatory markers including CRP and cytokines are mixed, and there is in 
addition a gap between results and possibilities for individualized treatments with 
anti-inflammatory capabilities in patients with detected low-grade inflammatory 
status.  
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2. Aims of the study 
The overall aim of this thesis was to investigate the CRP levels and changes isolated 
and in relation to cognition in a current episode of psychosis in clinically relevant 
sample. The investigations were conducted in a pragmatic design.   
Specific aims 
1. To investigate the relationship between CRP level and cognition in the acute 
phase of psychosis (paper 1).  
2. To study the correlation between initial changes in CRP levels and later 
changes in cognition during the first 6 months after acute psychosis (Paper 2). 
3. To investigate the effect of antipsychotic drug treatment on CRP levels in acute 
phase of psychosis and throughout the 1-year follow-up (paper 3). 
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                              3. Methods 
3.1 Setting 
3.1.1 Recruiting centers 
Bergen psychosis Project (BP) 
Haukeland University hospital, Bergen, 226 patients 
 
BestIntro 
Haukeland University Hospital, Bergen 102 patients 
Stavanger University Hospital, Stavanger 13 patients 
Medizinische Universität Innsbruck, Innsbruck 24 patients 
St. Olav’s University Hospital, Trondheim 5 patients 
3.2 Study population 
Patients with an acute psychotic episode and indication for oral antipsychotic 
treatment were included in the studies. 
3.2.1 Inclusion and exclusion criteria 
BP 
The inclusion criteria were as following:  
- Age  18 years. 
- Admitted to the psychiatric emergency ward for symptoms of psychosis, 
determined by a score of ≥ 4 on one or more of the PANSS (17) items of 
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delusions (P1), hallucinations (P3), grandiosity (P5), suspiciousness/ persecution 
(P6) or unusual thought content (G9). 
- Being able to cooperate on clinical and laboratory assessments. 
- Being candidate for oral antipsychotic drug therapy with one of the four first-line 
atypical antipsychotics available in Norway.  
The current first-line atypical antipsychotics of the trial were risperidone, olanzapine, 
quetiapine, and ziprasidone. Patients were included consecutively due to psychosis 
based on the presence of psychotic symptoms independent of the diagnostic group. 
The diagnostic evaluations were conducted by the treating clinicians. The participants 
had to meet ICD-10 (401) diagnostic criteria for schizophrenia, schizoaffective 
disorder, acute and transient psychotic disorder, delusional disorder, drug-induced 
psychosis, bipolar disorder except manic psychosis, and major depressive disorder 
with psychotic symptoms. The initiation of antipsychotic treatment before the 
determination of diagnosis was conducted in order to keep the naturalistic design 
similar to common clinical practice. 
The exclusion criteria were being unable to use oral antipsychotics, candidates for 
electroconvulsive therapy, experiencing a manic psychosis state, being unable to 
cooperate reliably during investigations, not understanding Norwegian language,  
organic brain disorder, such as dementia, and using clozapine. 
BestIntro 
The inclusion criteria were as following:       
- Age  18 years. 
- Symptoms of psychosis compatible with a diagnosis within the schizophrenia 
spectrum according to (F20-F29) of the ICD-10 (401) and DSM-4 (402).  
- A score of ≥ 4 on one or more of defining PANSS items P1, P3, P5, P6 or G9.  
- Being candidate for oral antipsychotic drug treatment determined by their treating 
physician or psychiatrist.  
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All patients were informed about the project by oral and written information, and 
written informed consent was necessary before inclusion. The diagnoses were 
determined by the study personnel consisting of specialists in psychology, residents 
and psychiatrists under supervision of senior consultant psychiatrists using the 
Structured Clinical Interview for the DSM-IV, (SCID-I) (402).  
The exclusion criteria included diagnosis other than the schizophrenia spectrum, not 
understanding Norwegian language, organic psychosis; antibody- verified limbic 
encephalitis, hypersensitivity to the active substances, pregnancy, lactation, and 
contraindications for the respective study drugs. 
3.2.2 Withdrawal criteria 
The criteria for study withdrawal were serious somatic events with indication for 
specific follow-up different from the protocol of the trials, pregnancy, and inevitable 
indication for concomitant use of more than one antipsychotic drug. Meanwhile, 
change of antipsychotic medication due to inadequate efficacy, side effects or 
interactions was not considered as an exclusion criterion.  
 
3.3 Study design 
BP 
The BP was a 2-year, prospective and pragmatic antipsychotic drug trial (403), and 
patients were consecutively recruited during March 2004- February 2009. The 
participants were admitted at psychiatric emergency ward of the Haukeland 
University Hospital in Bergen, Norway, which had a catchment area of about 
400,000. Assessments were performed at baseline, discharge or latest after 6 weeks, 
after 3, 6, 12 and 24 months. The assessments were conducted by raters blinded to the 
treatment. The patients were consecutively randomized to a sequence for treatment 
with 1 of 4 atypical antipsychotics consisting of olanzapine, quetiapine, risperidone or 
ziprasidone. The patient was offered the first drug in a random sequence. The 
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randomization was open to the patient and treating psychiatrist/ physician, who both 
could discard the number 1 atypical antipsychotic on the list, due to medical 
contraindications or previous adverse experiences with the drug. The next drug on the 
list could then be chosen, and the same principle was followed throughout the 
sequence. In each sequence, the atypical antipsychotic listed as number 1 defined the 
Randomization group, and the chosen atypical antipsychotic, regardless of 
randomization group, defined the First choice group. If a patient already used an 
antipsychotic medication at admission, no wash-out was performed before starting the 
study medication. In the case of randomization to the already used drug, the agent 
would be continued, with possibility for dose adjustment. The treatment regimen was 
open for the patient and physician. The minimum interval accepted for the first 
follow-up was one week, and discharge from the hospital before one week was the 
main reason for drop-out between baseline and discharge. 
BestIntro 
The BestIntro was a 1-year, randomized, head-to-head comparison study of 
amisulpride, aripiprazole and olanzapine. The participants were assessed at baseline, 
after 1week, 3 weeks, 6 weeks, 3 months, 6 months, 9 months and 12 months. Patients 
were consecutively recruited between October 2011- December 2017 through a multi-
centre cooperation between the Division of Psychiatry at Haukeland University 
Hospital, Stavanger University Hospital, and St. Olav University Hospital in Norway 
and the Medizinische Universität Innsbruck in Austria. The randomization and 
process were practically identical to the above –mentioned procedure for BP, however 
with some differences regarding assessments, which will be discussed under data and 
variables.  
3.4 Treatment 
The study medications were prescribed as tablets, and the patient’s psychiatrist or 
treating physician had the responsibility for the initiation, dosage and any subsequent 
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changes or termination of the study medication. The dosage of the antipsychotic drug 
or other medication was within the dosage range set by the Summary of Product 
Characteristics. The dosage ranges for BestIntro were 50-1200 mg/ day for 
amisulpride, aripiprazole 5-30 mg/ day for aripiprazole and 2.5-20 mg/ day for 
olanzapine. In order to resemble usual clinical practice, concomitant medications 
were permitted with the exception of additional antipsychotic drugs which were not 
allowed, in line with current treatment guidelines (404). The exception was cross-
titration during antipsychotic drug switches.  
3.5 Data and variables 
BP  
The assessment included background information, medical history, laboratory blood 
tests including CRP, urinalysis for illicit drugs and ECG at admission, while 
measurement of blood pressure, BMI, and psychometric assessments were conducted 
at all visits. Blood samples were collected from the fasting patients at 08-10 a.m. for 
analyses of CRP levels. There was a change in the laboratory’s CRP analysis methods 
in January 2005, and hence only data obtained after this change is reported in the 
present work. The method used is the Tina-quant C-reactive Protein (Latex) from 
Roche Modular P®, which measures CRP levels >1.00 mg/L. 
The psychometric assessment instruments were internationally certified, and assessed 
symptomatology of psychosis with PANSS, depression with Calgary depression rating 
scale (CDSS) (405), illicit drug use with Clinical drug and alcohol use scales 
(CDUS/CAUS) (406), general clinical impression with Clinical global impression 
(CGI) (407) and functioning with Global assessment of functioning-split version, 
Functions scale (GAF-F) (402). Cognitive functions were assessed with the 
Repeatable battery for the assessment of neuropsychological status (RBANS) (408, 
409), Trail making test (410), Controlled Oral Word Association Test COWAT (411); 
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Rey Osterrieth Complex Figure Test (ROCF) (412); California Computerized 
Assessment Package-Continuous Performance Test (CalCAP CPT) (413); The 
California Verbal Learning Test (CVLT) (414); Wechsler Adult Intelligence Scale- 
III-Revised (WAIS-III-R) (415) and Wechsler Memory Scale-Revised  (WMS)-R 
(416). Cognitive functions were assessed according to the Table1. 









RBANS A language 
 










RBANS A visuospatial/ 
constructional 
RBANS B visuospatial/ 
constructional   
WAIS-III  Digit Symbol-coding 




Attention  RBANS A attention RBANS B attention WAIS-III  Digit Span 
Digit Vigilance Test (time) 
CalCAP CPT  (Choice Reaction 
Time/Sequential Reaction Time) 
Trail Making test B  
Stroop colour/word conflict (time) 
 
WAIS-III  Digit Span 
CalCAP CPT  (Choice Reaction 
Time/Sequential Reaction Time) 
Stroop colour/word conflict (time) 
 
Learning  RBANS A immediate  
memory 
RBANS B immediate  
memory 
CVLT-II (Immediate Recall)  
WMS-R Logical Memory 
WAIS-III  Digit Span 
 
WMS-R Logical Memory 
WAIS-III  Digit Span 
Memory   RBANS A delayed  
memory 
RBANS B delayed  
memory 
CVLT-II  (Delayed Recall) 
ROCF Delayed recall 
 
ROCF Delayed recall 
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Notes:  
*Mean follow-up time at T2 was 4.1 weeks after baseline. RBANS (Repeatable Battery for the 
Assessment of Neuropsychological Status); WAIS-III (Wechsler Adult Intelligence Scale); COWAT 
(Controlled Oral Word Association Test); ROCF (Rey Osterrieth Complex Figure Test); CalCAP 
CPT (California Computerized Assessment Package-Continuous Performance Test); WMS-R 
(Wechsler Memory Scale-Revised).   
 
BestIntro 
The assessment procedures resembled BP, except for the neurocognitive assessment 
blood tests, and additional structural and functional MRI. Blood tests were conducted 
at all visits and included CRP, in addition to urinalysis for illicit drugs. Blood samples 
were collected from the fasting patients 08-10 a.m. The CRP level was measured by 
the Tina-quant C-reactive protein (Latex) method from Roche Modular P®, which 
measures CRP levels > 1 mg/L. The neurocognitive assessments of the BestIntro are 
not discussed in this thesis, since paper 3 from this study investigated the CRP levels, 
and not cognitive function. 
3.6 Statistics 
SPSS software version 20.0 and 24.0 were used for baseline analyses, group 
comparisons and predictions (417). Descriptive analyses were mean, standard 
deviation (SD), and frequency. Comparisons were analysed with correlations and 
multiple regressions for continuous data, analysis of variance (ANOVA) and 
Independent samples T-tests for differences in continuous variables on group factors, 
while cross tabulations with 2 tests were used for categorical data. Linear regression 
analyses were also used for adjusting for potential confounders. The level of 
statistical significance was set at α = 0.05, two-sided.   
Mplus version 7 and 8 were used to estimate level and change in all three studies 
(418, 419). Standard Mplus models use all available data under the “missing at 
random” assumption (420, 421), which minimize the effect of missing data and 
improves the generalizability (422, 423).  
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The robust maximum likelihood was used to give unbiased standard errors if outcome 
variables were found to be non-normal (424). If analyzing more than two 
measurement points (paper 2 and 3), linear change was first tested and evaluated with 
standard fit measures (425, 426). Satisfactory fit is indicated by statistically non-
significant chi-square, normed fit index (NFI) and Tucker-Lewis index (TLI) < .95, 
and root mean square error of approximation (RMSEA) < .05 (close fit), < .08 (fair 
fit) or < .10 (Mediocre fit), including RMSEA confidence intervals and probability of 
close fit in the population (427, 428). In addition, the residual results and plots of the 
observed and estimated level and change were used to evaluate the standard linear 
change assumption. If model did not fit data very well, latent piecewise models or 
contrast score models (latent variable difference model) were tested, describing 
limited intervals or differences between the measurement points. If models were 
found to be too simple (paper 1), or too complex regarding shape of change and the 
number of estimated parameters, residuals or other parameters had to be fixed to zero 
in order to identify the model (429, 430). In paper 3, lag one residual relations were 
estimated in order to account for stability in variance not accounted for the model 
(431).  
After fitting the level and change, predictors were added to the model. Control 
variables were accounted for in order to reduce biases. Variables not accounting for 
any relations were removed and model re-estimated based on a backward hierarchical 
procedure (432), a procedure that improves the probability to reveal suppressor 
relationships. In paper 3, two contrast variables were used to analyze medication 
differences of aripiprazole and olanzapine in relation to the reference drug 
amisulpride. Model constraints were used to compare the two regression weights also 
to compare the difference between aripiprazole and olanzapine. Both randomized and 
actual used medications were analyzed in separate models. Interaction terms were 
added to study medication differences dependent on relevant covariate variables.   
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3.7 Approvals and ethical considerations 
The BP and the Best Intro were approved by the Regional Committee for Medical 
Research Ethics West-Norway and the Norwegian Social Science Data Services. The 
projects were financed by the Research Council of Norway, the Western Norway 
Regional Health Authority and Division of Psychiatry, Haukeland University 
Hospital, and were independent of financial or marketing support from the 
pharmaceutical industry.  
Regarding the BP, the approval was granted to a two phase design. The first phase 
(quality assurance phase) was from admission to discharge/latest after 6 weeks, and 
was approved by the ethics committee to include the eligible patients prior to 
informed consent, assuring all acute psychotic patients guideline-concordant 
treatment. The second phase (research phase) was from discharge/latest after 6 weeks, 
based on informed consent, and included follow-up visits 3, 6, 12, and 24 months 
after admission. The procedures of this phase were beyond usual clinical standard, 
such as collections of data for use in psychiatric basic research within genetics and 
brain functional imaging.  
The BestIntro was in addition approved by the Norwegian Medicines Agency, the 
Etikkommission der Medizinische Universität Innsbruck, and the Austrian Federal 
Office for Safety in Health Care (BASG). The Best Intro was conducted in 
accordance with Good Clinical Practice (GCP) standards (433), and the Norwegian 
Health Research Act (434). Clinical monitoring in accordance with International 
Conference on Harmonisation - GCP (ICH-GCP) was conducted by the Department 
of Research and Development, Haukeland University Hospital in Norway, and by the 
Clinical Trial Centre at the Medical University Innsbruck in Austria. Informed 
consent was needed prior the RCT inclusion and randomization.  
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                        4. Results 
4.1 Paper I 
A total of 124 consecutive patients in acute phase of psychosis admitted to the 
psychiatric emergency unit were included in this study, a sub-study of the BP (67.7% 
male, and mean age 33.5 years). At admission 51.6% of patients were antipsychotic-
naïv, with a mean CRP level of 3.6 (SD 5.2), and mean overall cognitive function t-
score of 37.8 (SD 7.7). This study reported data for all groups collectively, as cross-
sectional baseline comparisons of treatment groups revealed no differences between 
the medication groups. The main findings were an inverse relationship at baseline 
between serum levels of CRP and overall cognitive performance, as well as for the 
subdomains delayed memory and attention. The association between overall cognitive 
function and CRP levels was particularly strong for the subgroup with schizophrenia. 
A total of 62 patients were retested for cognitive function at follow-up after 28.3 days 
(SD 11.1), and there was no association between CRP levels and cognitive function at 
the end of the acute phase. Furthermore, the baseline CRP level predicted the overall 
cognitive change during the follow-up interval. There were no statistically significant 
associations between the CRP level and the scores of PANSS total, PANSS positive, 
negative, and general psychopathology subscales, the CDSS, the GAF-F, and the CGI.  
4.2 Paper II 
A total of 208 (68.8 % male and mean age 33.5 years) consecutive BP patients in 
acute phase of psychosis who had data in one or more of the outcome variables of 
CRP and/or cognition were included in this study. This study reported data for all 
treatment groups collectively, and did not compare treatment groups. Measurements 
of CRP and cognitive performance were conducted at baseline (T1) and after 28.3 
days on average (T2). Cognition was also assessed after 3 months (T3) and 6 months 
(T4). At baseline the mean CRP level was 4.0 (SD 8.3), the mean overall cognitive 
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function t-score was 38.3 (7.7), and 44.2 % were antipsychotic- naïve. The main 
finding of the present study was that the global cognitive performance continued to 
improve from the initial phase of acute psychosis (T1-T2) to the later phase (T2-T4), 
and this improvement was predicted by the reduction of the CRP level as observed 
during the initial phase (T1-T2) of the treatment. Patients with most reduction in CRP 
showed the most improvement in global cognitive performance, compared to those 
with a smaller reduction or an increase in CRP. The different cognitive subdomains 
showed different time-dependent profiles of improvement, with memory and attention 
improving significantly also in the later phases. An inverse association between 
change in CRP level and verbal abilities (T2–T4 interval), and attention (T2–T3 
interval) were found, in addition to similar associations for some of the other 
cognitive subdomains. For patients with CRP < 10 mg/L (N = 191), the association 
between changes in global cognitive performance (T2-T4), verbal abilities (T2-T4), 
and attention (T2-T3), and CRP level changes remained unchanged. After adjustment 
for the covariates metabolic syndrome, smoking, being medication naïve, illicit drug 
use, and the educational level, the association between baseline CRP level and global 
cognitive performance for the whole follow-up remained essentially unchanged. In 
sensitivity analysis of the sub-sample of patients diagnosed within the schizophrenia 
spectrum change in CRP did not predict change in global cognition score, but 
predicted change in attention for the T1-T2 and T3-T4 intervals respectively. 
4.3 Paper III  
A total of 128 (64% male, and mean age 31.9 years) consecutive in- and out-patients 
with symptoms of acute phase psychosis were included in this study. The patients 
were recruited through the BestIntro study, of which 39% were antipsychotic-naïve. 
The sample represented patients with symptoms of acute psychosis compatible with 
schizophrenia spectrum disorders. There was a statistically significant increase in 
CRP levels during the first 1-3 weeks of the study for the whole group, and the 
increased levels lasted for 52 weeks. The three antipsychotics showed different 
effects on CRP levels, with aripiprazole reducing it for the first week of treatment. 
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Antipsychotic-naïve patients had lower levels of CRP, but had an increase upon 
medication similar to the previously medicated patients.  
Analyses of interaction effects revealed an initial increase followed by decrease of 
CRP levels in drug-naïve aripiprazole treated patients, with the opposite pattern for 
previously medicated patients. Besides, lower baseline level in CRP was associated 
with being medication naïve, having lower BMI levels and the absence of CVD. The 
present study also found that a higher baseline BMI was associated with stronger 
reduction in CRP in the 1-3 weeks interval.  
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5. Discussion  
5.1 Discussion of main results 
In this section the results from paper 1 and paper 2 will be discussed first, since the 
papers were thematically united on the association between CRP level and cognitive 
function. The results from paper 3 with regard to the effect of antipsychotics on CRP 
will be thereafter be discussed.   
5.1.1 Association between CRP level and cognitive function  
The main findings of paper 1 were the inverse relationship between baseline CRP 
level and overall cognitive performance, delayed memory, and attention, respectively. 
The findings are in line with one of the first studies on this topic, where elevated CRP 
level was associated with cognitive impairment in individuals with schizophrenia 
(236), followed by other studies on this topic (435-437). However, paper 1 adds new 
evidence also with regards to the longitudinal perspective, and antipsychotic-naïve 
patient group.  In one of studies, elevated CRP levels were correlated with poorer 
cognitive functioning of general intellectual ability, abstract reasoning, memory, 
working memory, semantic memory, learning abilities, attention, mental flexibility, 
and processing speed (435). A recent study found significant working memory 
differences between elevated (CRP ≥ 3) and normal CRP levels in chronically ill 
patients, which sustained after adjusting for BMI (237). Moreover, the same study 
showed for the first time that CRP level significantly and inversely, predicted the 
cortical thickness in most (8/9) of the brain regions, specially involving frontal lobe 
which might be especially sensitive to inflammation (237). An inverse relationship 
between CRP levels and cortical thickness in prefrontal regions, and reduced memory 
performance in patients with schizophrenia support the evidence for involvement of 
inflammatory processes in the cognitive impairments in psychosis (438-441).  
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In our sub-analyses of only patients with CRP levels < 15 mg/ L (to exclude acute 
inflammation), strengthening of the inverse association between CRP levels and 
overall cognitive performance was observed, while the association remained 
significant between CRP levels and the cognitive subdomains except immediate 
memory. Secondary analysis including only the schizophrenia sub-group showed that 
the inverse association between CRP levels and overall cognitive performance was 
markedly increased, which might indicate that in the schizophrenia sub-group the 
acute phase inflammatory response underpins the cognitive dysfunction.    
There was in addition a significant increase in cognitive performance between 
baseline and follow-up after 4/latest 6 weeks, with a stronger increase in overall 
cognition in patients with higher baseline CRP levels. This effect might be at least 
partly due to the illness phase, with regard to cases of first-episode psychosis/ hyper-
acute state and reflecting the higher baseline CRP level. The patients were included 
before providing the informed consent, which might have contributed indirectly to 
assessment in an earlier phase of psychosis. 
We, however, did not find statistically significant correlations between CRP level and 
other measures of psychopathology including psychosis symptoms, depression, or 
functioning. This is in line with the above-mentioned study (237) and another cross-
sectional study (236), where no association between CRP and PANSS symptom 
severity was found. A potential explanation might be the fact that cognitive symptoms 
often manifest prior to psychotic symptoms. However, there are also findings on 
greater severity of negative and general symptoms in patients with schizophrenia 
associated with elevated CRP levels (228).  
Moving to paper 2, the main findings were that the global cognitive performance 
continued to improve beyond the initial phase (T1-T2) of acute psychosis to the later 
phase T2-T4, however, being most pronounced during the T1-T2 (T1: baseline, T2: 
after 4 weeks/latest 6 weeks, T3: 3 months and T4: 6 months). Similar associations 
were found for several of the cognitive subdomains, such as improvement in verbal 
abilities, learning and attention during the T1–T2 interval, and in memory and 
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attention during the T2–T4 interval, respectively. The course of cognitive 
performance in patients with acute psychosis has been studied over decades. Several 
studies have suggested stability or decline in cognitive functioning (442-445). 
However, there is increasing evidence for improvement in cognitive function. A 
follow-up study of FEP schizophrenia spectrum disorders with intervals of 1-year and 
3-years showed that, the cognitive performance of the patients improved in all 
domains similar to controls, except for verbal and visual memory, which showed 
greater improvement in controls (70). Another longitudinal study demonstrated 
improvement of general cognitive function, working memory, and verbal learning 
after 12 weeks, but these changes were mediated by improvements in both positive 
and negative symptoms (389). A recent longitudinal study of FEP patients showed 
improvement in verbal- learning and fluency after one year (446). Similarly, cognitive 
improvement in almost all domains was found in schizophrenic adolescents, after six 
months of treatment with antipsychotics (447). Improvement in working memory after 
12 weeks of antipsychotic treatment in FEP antipsychotic-naïve patients is among 
recent findings (448). 
Regarding our observations of interval related improvements of cognitive 
performance, they might be influenced by the phase where treatment was initiated. In 
first episode patients, significant improvement in cognition has been reported in FEP 
patients from as early as 3 months after treatment (389), after 3-years (449) and up to 
5-years follow-up of FEP or recent-onset schizophrenia (450). Cognitive function in 
the chronic stage of the illness is described as static, with no significant improvements 
(451). These finding together with our results might support the idea that by adequate 
treatment in the early stages of psychosis, the greater improvements in cognition will 
be achieved.  
We found furthermore, that a reduction in the CRP level in the T1-T2 interval was 
associated with an increase in global cognitive performance and verbal abilities in the 
T2–T4 interval, respectively, and in attention for the T2–T3 interval. Sub-analysis of 
patients with CRP < 10 mg/L, showed sustained above-mentioned results. Secondary 
analysis of the sub-sample of schizophrenia spectrum disorders showed that change in 
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CRP level did not predict T2-T4 change in the global cognitive performance, but 
predicted improvement in attention for the T1-T2 and T3-T4 intervals. Our findings 
are in contrast to another longitudinal study, where CRP levels did not predict 
changes in cognitive performance (452), which, however, included chronic phase 
patients with average illness duration of 22.5 years, reflecting a lower potential for 
improvements in inflammatory correlated cognitive dysfunction. Another study 
showed that elevated CRP levels (3-10 mg/L) at baseline predicted significant 
worsening of PANSS- positive and general psychopathology, but not cognitive 
symptoms, which is different from our study results. Their participants were, 
however, not in acute phase psychosis (453). Our findings indicates that our sample 
represent early phase of acute psychosis, and suggests that reduction of CRP level 
during the initial phase of acute psychosis, have impact on improvement in cognitive 
functioning in later phases.  
Finally, after adjustment for the covariates metabolic syndrome, smoking, being 
medication-naïve, illicit drug use, and the educational level, the association between 
baseline CRP level and global cognitive performance for the whole follow-up 
remained essentially unchanged. Overall, with some differences after adjustment for 
confounders, and sub-group analysis, baseline CRP level and changes were associated 
with different pattern of improvement in cognitive functioning in our 6 months 
follow-up study of the patients with patients admitted for acute psychosis. There was, 
thus of essential interest to investigate whether different atypical antipsychotics can 
show any anti-inflammatory effects via changes in CRP level.  
5.1.2 Effect of antipsychotics on CRP level 
The main findings in BestIntro study regarding CRP levels, were the statistically 
significant differences between the study antipsychotics, and modification of the 
relationship between antipsychotic drug and CRP by previous exposure to 
antipsychotic drugs. We showed also an increase of CRP levels in the 1-3 weeks 
interval for the whole group. 
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In the group of aripiprazole as First choice drug there was a statistically significant 
reduction of the CRP level compared to olanzapine and amisulpride during the first 
week of treatment. Our findings are in line with results from the study of 405 stable 
patients with schizophrenia, which found that aripiprazole was the only antipsychotic 
drug associated with decreased CRP levels compared to the other antipsychotics; 
quetiapine, olanzapine, amisulpride, clozapine, loxapine, risperidone zuclopenthixol, 
paliperidone, and cyamemazine (399). Their CRP cut-off was dichotomized as 
detectable/undetectable, and the authors mentioned the recommended cut-off of CRP 
<3 mg/L, but they used this approach to manage the statistical challenge of CRP 
distribution, which might lead to loose possibility of 0 mg/L <normal CRP level < 3 
mg/. The results identified however, the reduction of CRP levels, which is the main 
aim of this topic. Another longitudinal study of aripiprazole 4 weeks follow-up in 
patients with chronic schizophrenia showed reduction in CRP levels (391).  
 Our other finding of the CRP lowering effect of aripiprazole in patients with prior 
use of antipsychotics might reflect a potential anti-inflammatory effect of aripiprazole 
on the pro- inflammatory state associated with earlier medications or a more advanced 
phase of the disorder. Antipsychotics might lead to metabolic changes including 
weight gain, increased lipid levels and increased CRP levels. Findings from The 
Clinical Antipsychotic Trials of Intervention Effectiveness Study (CATIE) showed an 
increase in CRP levels after 3 months treatment with antipsychotics (including 
perphenazine, olanzapine, quetiapine, ziprasidone, and risperidone, and 45% used 
antipsychotics at baseline), and the highest median levels for CRP were found for 
quetiapine and olanzapine groups (454). A recent 12 months follow-up study of FEP 
showed significant increase of CRP levels, weight gain, and increase in waist 
circumference, whereas 89% of patients used antipsychotics at baseline including 
olanzapine, risperidone, quetiapine and others (aripiprazole, sertindole, ziprazsidone) 
(455). In another study of patients with schizophrenia who used olanzapine, 
quetiapine, clozapine or risperidone significantly higher levels of CRP and IL-6 were 
shown compared to non-medicated group (400).  
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In our study the aripiprazole group showed furthermore, an increase in CRP levels for 
the last follow-up period 39-52 weeks among those previously antipsychotic 
medicated, whereas the antipsychotic- naive patients had a significant reduction in 
CRP levels for this period. 
Taken together, we identified a pattern of initial increase followed by decrease of 
CRP levels in drug-naïve aripiprazole treated patients, with the opposite pattern for 
previously medicated patients. This might indicate an initial pro-inflammatory 
activation followed by a subsequent anti-inflammatory effect in the drug-naïve group. 
The interpretation of this pattern can only be speculative, but could include factors 
such as delayed anti-inflammatory effect of aripiprazole or contrasting effects of the 
drug in different phases of the psychosis. A recent study of schizophrenia out-patients 
with at least 1 year antipsychotic treatment showed substantially elevation of CRP 
levels in acute psychosis in 60% of the patients compared to 43% of chronically ill 
patient. The latter group showed significantly lower CRP levels than the acute 
psychosis group, suggesting the decreasing effect of antipsychotic treatment, and 
inflammatory response in acute psychosis phase. They found furthermore, a 
significant decrease in CRP levels at repeat admission compared to initial admission, 
but CRP at both admissions was significantly elevated compared to the clinical cut-
off of <3 mg/L. The authors commented that after adjustment for BMI, with remained 
elevated neutrophil/lymphocyte ratio (NLR), the elevated inflammation would not be 
fully explained by BMI in acute phase psychosis (237). Furthermore, antipsychotics 
overall, seem to increase levels of CRP in the long term. As CRP may be associated 
with the increased risk of CVD seen in patient groups using these medications this is 
an important finding that needs further exploration as a potential target to reduce 
morbidity and mortality in this patient group 
The mechanisms by which antipsychotic medications affect the inflammatory 
pathways remain unknown. Several studies have shown alterations in the levels of 
cytokines in both pro- and anti-inflammatory directions following antipsychotic drug 
use in FEP patients and individuals with schizophrenia with acute phase psychosis 
(176, 394, 395, 398). In our study aripiprazole seemed to differ from both amisulpride 
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and olanzapine, regarding the changes in CRP levels, and findings with regard to the 
potential anti-inflammatory effect of aripiprazole are presented here. 
In the above-mentioned study of 4 weeks treatment with aripiprazole (391) reduction 
of several pro-inflammatory cytokines (IL-6, TNF-α, IL-1ß, IFN-γ, IL-12, IL-23) and 
2 anti-inflammatory cytokines (IL-4, TGF-ß1) respectively, together with markedly 
increase in anti-inflammatory cytokine IL-10 were found, supporting the immune-
modulatory effect of aripiprazole.  
Reduction of IL-6 and TNF-α independent of metabolic effects have been also shown 
in an ex vivo study by stimulation of human blood mononuclear cells with olanzapine 
or aripiprazole, suggesting the reduced secretion of inflammatory cytokines in human 
immune cells by olanzapine and aripiprazole (456). In an rodent study of microglial 
cells, aripiprazole inhibited release of TNF-α from IF-γ-activated microglial cells 
modulated by intracellular calcium signalling (457). In an ex vivo study of 
macrophage-like cells, aripiprazole inhibited strongly and dose-dependently 
production of the inflammatory mediators nitric oxide and prostaglandin E2, by 
suppressing intracellular inflammatory pathways in macrophage like cells (458). 
Overall, existing evidence suggest that aripiprazole affects different cellular 
pathways, in addition to effects on gene expression different from other 
antipsychotics (459). An in vivo study showed that acute administration of 
aripiprazole did not have effects on dopamine release in the medial prefrontal cortex 
or the striatum, but it could strongly increase levels of dopamine extracellular 
metabolites and inhibit levels of extracellular serotonin metabolites in both regions. 
Meanwhile, chronic administration of aripiprazole showed  ‘stabilization’ of 
dopaminergic effects, with a reduction in dopamine concentrations and weaker effects 
on both dopamine and serotonin extracellular metabolites (460). The different effects 
of aripiprazole depending on the administration duration might partly explain the 
time/phase effect pattern identified in our study, however without a direct link to the 
inflammatory pathways.  
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Moving beyond the level of the specific study medications, in line with existing 
evidence lower baseline levels of CRP were associated with being antipsychotic- 
naïve, having lower BMI levels and low levels of CVD risk factors (230, 461-463). In 
a recent study of 106 patients with schizophrenia, BMI was positively correlated with 
CRP levels, independent of age, sex, race, education or cotinine (a metabolite of 
nicotine) levels (464). Furthermore, CRP was negatively correlated with HDL in the 
total sample, in the overweight/obese patients, and not in the normal-weight patients. 
The authors interpretation was that overweight/obesity was associated with increased 
inflammation and dyslipidemia in patients with schizophrenia (464), in line with our 
finding of which, a higher baseline BMI was associated with stronger reduction in 
CRP in the 1-3 weeks interval. Taken together, the stronger CRP reduction in these 
putatively more inflammatory challenged groups points toward an immune-
modulatory effect of antipsychotics. An indirect effect of aripiprazole via its lower 
propensity to induce metabolic changes than olanzapine and the other new generation 
antipsychotics might also have contributed to the CRP reduction. 
To summarize, we found a statistically significant different CRP altering profile in the 
patient group who received aripiprazole, with initial significant CRP reduction in 
patients who used antipsychotics prior to inclusion compared to antipsychotic-naïve 
patients after one week of treatment. An opposite pattern was observed during the last 
3 months of treatment.  
Our findings are in line with some other studies so far, as they confirm differences 
between antipsychotics regarding effects on the immune system, yet the role of the 
influence of possible mediating effects of metabolic changes induced by different 
antipsychotics needs to be elucidated in further studies,    
5.1.3 Clinical implications 
To summarize, there is evidence for low-grade inflammation in around 40% of 
patients with schizophrenia (465-467), with identified elevated levels of CRP at least 
in a proportion of individuals with schizophrenia (227, 228, 231, 468, 469). However, 
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a recent meta-analysis of immune parameters and their variability in patients with 
psychosis showed elevated levels of IL-6, IFN-γ, and IL-17 (robust to sensitivity 
analysis) in antipsychotic-naïve FEP patients. IL-6 showed reduced variability in 
patients, suggesting this cytokine to be a core component of the pathophysiology of 
psychosis. The unimodal distribution of raw data in 94%  of psychotic patients and 
100% of controls suggests that alterations in the immune system are rather a general 
feature of psychosis than an immune subtype of psychosis (470). 
Overall, we have shown the essential role of inflammatory pathways in schizophrenia 
by investigating the impact of CRP level and changes in both acute phase psychosis 
and in later phases with regard to symptomatology, especially cognitive impairment. 
Finally, we showed and discussed the different effect pattern of study antipsychotic 
drugs on CRP levels.   
The measurement of CRP is reliable, widely used in clinical practice, and therefore, 
might have potential to be used in both screening, and follow-up of patients with 
immunologically activated component. The fact that elevated CRP levels are 
correlated with decreased cortical thickness in several brain regions, cognitive 
dysfunction, more severe symptomatology, poor prognosis support the role of CRP in 
schizophrenia spectrum disorders. Furthermore, elevated CRP is associated with 
cardiovascular risk for CRP > 2 mg/L (471), and increased all- cause mortality (472). 
There is, therefore convincing that the lower CRP level, the better outcome. The 
easily and consistently measurement of CRP in conjunction with diagnosis could be 
used to identify patients in inflammatory activated state, which might provide a 
guidance regarding the proper choice of antipsychotic drug with/ without adjunctive 
anti-inflammatory agents.  
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5.2 Methodological considerations   
5.2.1 Research design 
The BP and BestIntro studies had similar clinical inclusion criteria for acute phase 
psychosis  by a threshold of  ≥ 4 on essential positive symptom items of the PANSS in 
line with other antipsychotic trial designs (473). However, the BP by including both 
depressive episode with psychotic symptoms, and drug-induced psychosis patients 
were diagnostically more heterogeneous than BestIntro, and considered to be as 
naturalistic as possible. Subsequent statistical sub-analysis in paper 1 and 2 were, 
thus, conducted to manage the heterogeneity. The paper 1 included all patients who 
had both baseline CRP measurement, and cognitive assessment, respectively. The 
paper 2 included all patients with data on one or more of the outcome variables (N = 
208), which provided analysis of a larger sample size. The BP study had a long 
follow-up interval of 2 years, which was a challenging aspect of the study design. 
However, with regard to the longitudinal perspective of paper 2, a follow-up interval 
of 6 months was chosen, in order to investigate the potential inflammatory related 
improvement of cognitive function. 
5.2.2 Assessment 
The baseline data for paper 1 were based on the baseline CRP levels, and cognitive 
assessments using RBANS, while the first follow-up after 4 weeks/latest after 6 
weeks were consisting only cognitive assessments. The lacking of the CRP level at 
follow-up was, however, handled by the appropriate statistical model. Reliability 
testing was performed for the PANSS ratings in both BP and BestIntro. The diversity 
of cognitive assessments in BP was another challenging aspect of paper 2. The 
RBANS (short battery) was used at baseline because of the active psychotic 
conditions that did not allow for a more comprehensive battery, and because the 
RBANS can be repeated. We used a more comprehensive cognitive battery after 3 
months (T3) to increase the clinical validity. In a preliminary analysis, a satisfactory 
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relationship between the RBANS and equivalent domains from the more 
comprehensive neuropsychological battery  3 months later emerged, even despite 
symptom-level differences at the two time points (474). A more detailed explanation 
for the complexity of cognitive assessments is provided in the manuscript of paper 2. 
With regard to the assessments in BestIntro relevant for paper 3, the same assessment 
approaches were conducted in all follow-up visits.  
5.2.3 Statistical considerations 
The used statistical models, such as latent growth model (LGC), were selected in the 
project planning phase. In addition to analysing level and change, both at group mean 
and individual level, this model uses all available data. As for instance in paper 2, 
data from patients with even only one observed value were used. Given the expected 
and challenging missing data, it is essential that this model manage this challenge by 
using all available data. Thus, LGC improves the generalizability of the results. The 
ordinary listwise deletion methods, like ANOVA repeated measures, result in lack of 
important information and restrict the generalizability to the population of patients 
being able to participate at all visits.  Furthermore, LGC makes it possible to analyse 
data from different number of visits with different follow-up intervals. However, 
these and most other methods do not rule out the possible “missing not at random” 
(MNAR) assumption, since we did not have the possibility to investigate the reasons 
or conditions among the dropping out participants. Sensitivity analyses could have 
been used to test the stability of parameter estimates under MNAR. However, such 
models have strict statistical assumptions, and such modelling was decided not to be 
included in the presented studies, which is important, as evaluating the quality of the 
studies is related to both precision of estimates and statistical power. Some models 
used, particularly the full model in paper 3, are complex with a large number of 
estimated parameters. Simulation could have been done in order to ensure statistical 
power in all parameters. However, no earlier studies with same model analysed in 
equal sample of patients have been found. Therefore, no ad hoc simulation could be 
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analysed. Regarding precision, the results should be replicated in samples larger in 
size. 
5.3 Strengths and limitations                                                                             
Strengths                                                                                                                     
The randomized naturalistic design is the main strength of both drug trial studies, with 
consecutive inclusion of patients with acute psychosis. Furthermore, the longitudinal 
perspective of studies was an essential strength, since most of the inflammatory-based 
studies are cross-sectional. Regional Committee for Medical Research Ethics allowed 
eligible patients to be included before informed consent were provided, and thus, the 
patients who were included in the first phase of the BP study might reflect the very 
initiate phase of acute phase psychosis. The relatively high percentage of 
antipsychotic naïve patients (51.6% in paper 1, 44.2% paper 2, and 39% paper 3) was 
an advantage with regard to the investigation of inflammatory processes involved in 
the pathogenesis of schizophrenia. Both studies were pharmaceutical industry 
independent. 
Limitations                                                                                                               
There are some limitations to the BP and BestIntro studies. The BP participants as 
mentioned earlier, were diagnostically heterogeneous, which makes the inference to 
certain diagnostic subgroups questionable. However, sensitivity analyses were used to 
provide results also at subgroup level. Diagnoses were obtained by the treating 
psychiatrist or psychologist, that might have reduced inter- therapist diagnosis 
reliability. In the BestIntro, this limitation effect was taken to account, and structured 
clinical interviews and diagnostic evaluations and conclusions were conducted by 
study psychiatrists or specialists in psychology. Both studies had substantial attrition, 
particularly in BP study (62 of 124 patients were assessed at the first follow-up 
regarding paper 1). Furthermore, the only available measurements of inflammatory 
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markers were the serum CRP levels, and white blood cell count (WBC) with cell type 
differentiation was unfortunately not conducted. 
We used cut-off of CRP ≤ 15 mg/l in paper 1, different from paper 2 and paper 3, 
which had cut-off of CRP ≤ 10 mg/l. Our choice of cut-off in paper 1 was based on 
the few existing publications focusing on CRP, and it was our first inflammatory 
related investigation. However, with increased evidence for the potential role of CRP 
in schizophrenia, we adjusted the CRP cut-off for paper 2 in line with other existing 
publications. The studies did not have a healthy control group, and thus, all 
participants were medicated by study medications, which might have influenced the 
raters conclusions. 
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                 6.Concluding remarks 
The presented findings support following conclusions: 
BP 
 CRP level in acute phase of psychosis is inversely associated with overall 
cognitive performance, as well as for the cognitive subdomains delayed 
memory and attention. The association between overall cognitive function and 
CRP levels was particularly strong for the subgroup with schizophrenia.  
 The global cognitive performance improved predominantly in the initial phase 
of acute psychosis, and continued to improve in the later phase at least up to 6 
months. 
 The improvement in global cognitive impairment was predicted by the 
reduction of the CRP level in the initial phase. The different cognitive 
subdomains showed different time-dependent profiles of improvement, with 
memory and attention improving significantly also in the later phases. 
BestIntro 
 There were differences between three atypical antipsychotics amisulpride, 
aripiprazole, and olanzapine regarding change of the CRP levels, both in acute 
and later phases of psychosis in schizophrenia spectrum disorders. The 
aripiprazole group showed a reduction of the CRP level compared to either 
olanzapine or amisulpride group, during the first week of treatment.  
 There was different pattern of change in CRP levels depending on the history 
of previous antipsychotic use. The aripiprazole group showed an initial 
increase followed by decrease of CRP levels in drug-naïve patients, with an 
opposite pattern for previously medicated patients.  
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                   7. Future perspectives 
Findings from the present study necessitate further investigations on the association 
between CRP levels and symptomatology including cognitive dysfunction in patients 
with schizophrenia spectrum disorders (BestIntro data). Furthermore, the effects of 
atypical antipsychotic drugs on potential link between CRP changes and 
symptomatology should be clarified.  
Other inflammatory markers such as cytokines as well as complement system related 
research in conjunction with genetical and brain imaging approaches, will provide 
essential evidence in this field, in order to achieve further understanding of the 
involvement of the inflammatory pathways in pathogenesis and treatment 
opportunities for patients suffering from long lasting burden of this disease group.  
The prospective endpoint might be the identification of the individuals with low-
grade inflammatory status, representing candidates for certain antipsychotics with 
favourable immune-modulatory profile and/or adjunctive anti-inflammatory agents. 
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Abstract
Background: Inflammatory processes have been implicated in the etiology of schizophrenia and related psychoses, in
which cognitive deficits represent core symptoms. The aim of the present study was to investigate possible
associations between the level of the inflammation marker C-reactive protein (CRP) and cognitive performance in
patients through the acute phase of psychosis.
Methods: A total of 124 patients were assessed at admittance to hospital and 62 patients were retested at discharge
or after 6 weeks at the latest, with measurements of the CRP levels and alternative forms of the Repeatable Battery for
the Assessment of Neuropsychological Status.
Results: There was an inverse relationship between overall cognitive performance and CRP level at admittance. The
association increased in sub-analyses including only patients with schizophrenia. In cognitive subdomain analyses
statistically significant inverse associations were found between the CRP level and Delayed memory and Attention,
respectively. No associations were found between CRP level and other measures of psychopathology including
psychosis symptoms, depression, or functioning. At follow-up the association between CRP level and cognition
was no longer present. There was a significant increase in cognitive performance between baseline and follow-up.
There was a stronger increase in overall cognition scores in patients with higher baseline CRP levels.
Conclusions: The findings indicate that signs of inflammation may serve as a state-dependent marker of cognitive
dysfunctions in acute psychosis.
Trial registration: ClinicalTrials.gov ID; NCT00932529, registration date: 02.07.2009
Keywords: Schizophrenia, Cognition, Inflammation, CRP
Background
Schizophrenia and related psychoses are severe mental
disorders characterized by positive and negative psych-
otic symptoms, cognitive dysfunction and functional de-
cline, with a lifetime prevalence close to 1 % [1]. Positive
symptoms were until recently considered the most
prominent features of the disorders as reflected also in
the major diagnostic manuals, but cognitive dysfunctions
have for the last decade been recognized as core features
of schizophrenia [2–5], and with greater impact on func-
tional outcome than the psychotic symptoms [6–10].
The etiology of schizophrenia remains to be clarified,
but genetic as well as environmental factors convey risk
[11]. Involvement of inflammation and the immune sys-
tem in the pathophysiology of schizophrenia has re-
ceived particular attention in recent years, fueled also by
the genome wide association study (GWAS) findings of
associations between markers in the immune system in-
cluding the major histocompatibility complex and
schizophrenia risk [12–15]. Furthermore, preclinical-,
postmortem-, brain imaging-, and pharmacological stud-
ies, as well as clinical evidence from drug naïve first
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episode patients, strongly suggest a role for the immune
system in schizophrenia development (see for example
[16–18] for updated reviews). Emerging evidence indi-
cates that immuno-inflammatory processes may be par-
ticularly relevant to the cognitive dysfunctions of
schizophrenia [19–21].
The C-reactive protein (CRP), an acute-phase reactant
synthesized in the liver, has for many decades been con-
sidered a reliable marker of inflammation [22]. With
regards to cognition, a negative correlation has been
found between CRP levels and cognitive impairment in
the elderly, although not consistently [23, 24]. Scattered
reports also exist of inverse associations between CRP
levels and cognitive function in severe depression [25],
and in bipolar disorder [26]. In schizophrenia, a recent
meta-analysis by Fernandes et al. [27] consistently found
elevated serum levels of CRP in both first episode and
chronic phase patients, irrespective of medication status.
Furthermore, an association between CRP levels and
positive symptoms but not negative symptoms of psych-
osis was found. To the best of our knowledge, investiga-
tions of associations between the CRP level and
cognitive dysfunction in schizophrenia are however
scarce, although an association between CRP levels and
cognitive functioning in patients with predominantly
chronic schizophrenia has been reported in one cross-
sectional study [28]. Studies involving patient samples
representative of the acute and early phases of psychosis
are missing, as are studies with longitudinal measure-
ments. We have previously demonstrated a statistically
significant time effect for overall cognitive improvement
in acutely admitted psychosis patients during 24 months
of follow-up [29], but have not so far examined changes
in the acute phase.
The main aim of our study was accordingly to investi-
gate the association between the CRP level and cognitive
performance in a clinically representative sample of pa-
tients with psychosis acutely admitted to hospital, with
repeated measurements in the acute phase.
Methods
The materials and methods used have been described in
greater detail elsewhere [30]. The study is part of a prag-
matic, randomized trial comparing second generation
antipsychotics (SGAs) in the treatment of psychosis. The
present paper reports data obtained at baseline in pa-
tients who underwent cognitive assessments at admit-
tance and at discharge or after maximally 6 weeks if not
already discharged (termed as follow-up). This time
period corresponds to the acute phase of treatment.
Patients were consecutively recruited from March 2004
until February 2009 from the Haukeland University
Hospital with a catchment population of about 400,000.
The study was approved by the Regional Committee for
Medical Research Ethics, and by the Norwegian Social
Science Data Services. The study was publicly funded
and did not receive any financial or other support from
the pharmaceutical industry. The Regional Committee
for Medical Research Ethics allowed eligible patients to
be included before informed consent was provided, thus
entailing a clinically relevant representation in the study.
The patients were asked at follow-up for written in-
formed consent. All adult patients were eligible for the
study if they were acutely admitted to the emergency
ward for symptoms of active psychosis as determined by
a score of ≥4 on one or more on the items Delusions,
Hallucinatory behavior, Grandiosity, Suspiciousness/per-
secution, or Unusual thought content in the Positive and
Negative Syndrome Scale (PANSS) [31] and were candi-
dates for oral antipsychotic drug therapy. Accordingly
the patient inclusion encompassed the consecutive re-
cruitment of a clinically representative sample of psych-
osis patients acutely admitted to hospital. All eligible
patients met the ICD-10 diagnostic criteria (http://apps.
who.int/classifications/icd10/browse/2010/en) for schizo-
phrenia, schizoaffective disorder, acute and transient
psychotic disorder, delusional disorder, drug-induced
psychosis, bipolar disorder except manic psychosis, or
major depressive disorder with psychotic features. The
diagnoses were determined by the hospital’s psychiatrists
or specialists in clinical psychology. Patients were ex-
cluded from the study if they were unable to use oral an-
tipsychotics, were suffering from manic psychosis or for
other behavioural or mental reasons related to the state
of illness were unable to cooperate with assessments, did
not understand spoken Norwegian, were candidates for
electroconvulsive therapy, or were medicated with cloza-
pine on admittance. Patients with drug-induced psych-
oses were included only when the condition did not
resolve within a few days and when antipsychotic drug
therapy was indicated.
Clinical assessments
Before inclusion, eligible patients underwent the PANSS
structured clinical interview. Intra-class correlation coef-
ficients (ICC) were calculated based on inter-rater as-
sessments and showed high inter-rater reliability (0.92).
Furthermore, the Calgary Depression Scale for Schizo-
phrenia (CDSS) [32], and the Clinical Drug and Alcohol
Use Scales (CDUS/CAUS) [33] were used, and the pa-
tients were rated according to the Clinical Global
Impression—Severity of Illness scale (CGI-S) [34], and
the Global Assessment of Functioning—Split Version,
Functions scale (GAF-F) [35]. A blood sample was col-
lected from the patients between 08 and 10 a.m. for ana-
lyses of CRP levels. There was a change in the
laboratory’s CRP analysis methods in January 2005, and
hence only data obtained after this change is reported in
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the present work. The method used is the Tina-quant C-
reactive Protein (Latex) from Roche Modular P®, which
measures CRP levels >1 mg/L. Antipsychotic drug doses
were converted to defined daily doses (DDDs), in ac-
cordance with the World Health Organization Collabor-
ating Center for Drug Statistics Methodology (http://
www.whocc.no/atc_ddd_index/). The basic definition of
the DDD unit is the assumed average maintenance dose
per day for a drug used for its main indication in adults.
Cognitive assessment
Cognitive assessments were conducted at baseline and at
follow-up. A brief neuropsychological screening instru-
ment with alternative forms; the Repeatable Battery for
the Assessment of Neuropsychological Status (RBANS),
was used to minimize potential practice effects [36–38],
since longitudinal studies on cognitive functioning usu-
ally do not address the issue of practice effects suffi-
ciently [39, 40]. Practice effects can be particularly
evident when there are short time intervals between re-
peated neuropsychological testing, and the effect seems to
be strongest from baseline to the second testing [41, 42].
The RBANS has previously shown good reliability and val-
idity in psychosis [43]. It takes only about 30 min to
complete, making it practical and feasible to use in the
acute phases of psychosis. The five cognitive domains
were: Language; Visuospatial/ constructional; Immediate
memory; Delayed memory; and Attention. Raw scores
from the neuropsychological variables were converted to
t-scores by means of the norms from the manual [44]. The
final summary score based on the mean t-scores across
the five cognitive domains defined the overall cognitive
function t-score.
Statistical procedures
Categorical and continuous data at baseline were ana-
lyzed using exact χ2 – tests and one-way ANOVAs in
the SPSS software, version 20.0 (IBM SPSS Statistics,
2011). To investigate the association between cognitive
performance and CRP levels bivariate analyses of correl-
ation were conducted. This was followed by linear re-
gression analyses to adjust for potential confounders
between cognition and CRP. These confounders in-
cluded years of education, as a proxy for socioeconomic
status which may have an impact on both CRP levels
and cognitive performance [45]; medication status (i.e.
being antipsychotic drug naïve or previously exposed to
antipsychotic drugs) prior to inclusion, as antipsychotics
may influence both CRP levels and cognition [46, 47];
tobacco smoking, which has been associated with both
elevation of CRP levels [48, 49] and enhancement of
cognition [50, 51]; drug abuse, as a relationship between
drug abuse and CRP has been established [52, 53]; and
finally, cardiovascular risk, as CRP has been identified as
a risk factor for cardiovascular disease (CVD) [54, 55]
and CVD has been associated with cognitive impairment
[56, 57]. A CVD risk score was calculated based on the
International Diabetes Federation metabolic syndrome
definition cut-off values (http://www.idf.org/webdata/
docs/IDF_Meta_def_final.pdf ), by which each factor
(obesity, raised triglycerides, reduced HDL cholesterol,
raised blood pressure, and raised fasting plasma glucose)
was dichotomized as absent (0) or present (1), giving rise
to a maximal sum score of 5 for the individual factors.
Latent Growth Curve (LGC) models of level and
change in CRP and cognition were analyzed with the
Mplus program, version 7.20 [58]. Such models describe
both mean levels and individual variations in level and
change. In addition, the relation between level and
change is estimated. Because of only two measurement
points, baseline and follow-up, the residuals had to be
pre-specified in order to identify the model [59]. Mplus
allows unequal individual time-spaced observations to
be analyzed [60], and time was specified as weeks. The
default estimator for LGC modelling is maximum likeli-
hood with robust standard errors (MLR), which is robust
for non-normal data [60, 61]. Standard Mplus models
use all available data under the “missing at random”
assumption and minimize the effect of missing data
[62, 63]. First, unconditional separate LGC models
were analyzed, then a model integrating level and
change in both CRP and cognition was used in order
to study the relation between baseline levels in one
variable as a predictor of changes in the opposite
variable, after accounting for the control covariates.
Variables not accounting for any relations were re-
moved and model re-estimated based on a backward
hierarchical procedure [64].
The level of statistical significance was set at α = 0.05,
two-sided.
Results
A total of 124 patients were included with serum CRP
level measurements and cognitive assessments at base-
line. The demographic and clinical characteristics are
shown in Table 1. One patient used concomitant anti-
inflammatory medication (prednisolone). None of the in-
cluded patients were diagnosed with inflammatory- or
immunological disorders or infections during the study.
Baseline
The mean CRP level with standard deviation (SD) at ad-
mission was 3.6 (5.2) mg/L and the mean overall cogni-
tive function t-score was 37.8 (7.7).
The cognitive subdomain t-scores were 40.5 (7.8); 45.8
(12.7); 35.7 (10.2); 37.6 (12.1); and 29.5 (8.9) for Lan-
guage; Visuospatial/ constructional abilities, Immediate
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memory; Delayed memory; and Attention, respectively
(Fig. 1).
In the primary analyses, the Pearson correlation test
revealed a statistically significant inverse relationship
between overall cognitive performance and CRP level
at baseline (Pearson correlation r = −0.247, R2 = 0.061,
p = 0.006) (Fig. 2). In a linear regression model with
overall cognitive performance as the dependent variable
and CRP, years of education, antipsychotic drug status
before inclusion, tobacco smoking status, drug abuse,
and CVD risk score as independent variables, the asso-
ciation remained statistically significant between cogni-
tive performance and CRP (B = −0.290; Beta = −0.198;
p = 0.031). No interaction effects were found between
CRP and any of the other independent variables that
significantly improved the model. In the secondary analyses
there were statistically significant inverse associations
between CRP level and Delayed memory (B = −0.484;
Beta = −0.213; p = 0.02) and Attention (B = −0.404;
Beta = −0.239; p = 0.012), whereas no association was
found between CRP and Language, Visuospatial/con-
structional abilities, or Immediate memory, respect-
ively. In a sensitivity analysis that included also the
PANSS positive symptoms scale score, the results
remained unchanged.
In Pearson correlation tests of the relationships be-
tween CRP and the PANSS total score, the scores of the
PANSS positive, negative, and general psychopathology
subscales, the CDSS, the GAF-F, and the CGI, respect-
ively, no statistically significant correlations were found
(r < 0.100 for all).
Based on visual inspection of the CRP levels versus over-
all cognitive performance scatterplot, the bulk of data were
in the lower end of the CRP levels (Fig. 2). Accordingly
sub-analyses were conducted that included only patients
with CRP levels <15 mg/ L (N = 119). The inverse associ-
ation between CRP levels and overall cognitive performance
was strengthened (B = −0.741; Beta = −0.300, p = 0.001). In
the cognitive subdomains statistically significant associa-
tions with CRP levels were found for all domains except
Immediate memory. When only the schizophrenia sub-
group (N = 36) was included, the inverse association be-
tween CRP levels and overall cognitive performance was
markedly increased ((B = −1.031; Beta = -0.529; p = 0.006).
In sensitivity analyses that included only the sub-
group of drug naïve patients (N = 64), the inverse relation-
ship between CRP level and overall cognitive performance
remained essentially unchanged compared to in the pri-
mary analyses with the full sample, although the correl-
ation was no longer statistically significant (B = −0.568;
Beta = −0.194; p = 0.187).
In sensitivity analyses excluding the patient using
prednisolone the results were unchanged.
Follow-up
A total of 62 patients were retested using the RBANS B
at follow-up. The mean interval between baseline and
follow-up was 28.3 (11.1) days. The mean PANSS total
and CGI-S scores were 53.9 (13.9) and 3.6 (1.0),
Table 1 Baseline demographics and clinical characteristics
(N = 124)
Characteristics
Gender N % of sample
Male 84 67.7
Female 40 32.3
Antipsychotic drug naïve 64 51.6
Alcohol use last 6 months
None 17 13.7
Misuse 15 12.1
Illicit drug use last 6 months
None 82 66.1
Use/ Misuse 25 20.2
Current tobacco smoking 64 51.6
Diagnosisa







Body Mass Index 23.5 4.6/ 15.8–40.3
Years of Education 12.5 2.7/ 8–22
PANSS Total 73.4 11.9/ 45–98
PANSS Positive 20.1 4.1/ 12–30
PANSS Negative 19.0 6.9/ 7–38
PANSS General 34.3 6.4/ 20–56
CDSS 6.2 5.0/ 0–23
GAF-F 30.5 4.9/ 18–45
CGI 5.2 0.6/ 4–6
RBANS t-score 37.8 7.7/ 20.2–58.8
N number of patients, SD standard deviation; Antipsychotic drug naive = No
life-time exposure to antipsychotic drugs before index admission; Misuse =
Misuse or Dependence according to the Clinical Drug and Alcohol Use Scales
(CDUS/CAUS), patients with no illicit drug use could be included in the category
alcohol use last 6 months; Schz and related = Schizophrenia and related disorders:
Schizophrenia, schizo-affective disorder, acute polymorphic psychotic disorder
with symptoms of schizophrenia, acute schizophrenia-like psychotic disorder,
delusional disorder; Acute = Acute psychosis other than those categorized under
Schz and related; Affective = Affective psychosis; Rest =Miscellaneous
psychotic disorders. All diagnoses are according to ICD-10; PANSS the Positive and
Negative Syndrome Scale, CDSS the Calgary Depression Scale for Schizophrenia,
GAF-F the Global Assessment of Functioning, split version, Functions scale, CGI the
Clinical Global Impression, severity of illness scale, RBANS the Repeatable Battery for
the Assessment of Neuropsychological Status
aPatients with missing diagnoses are not included in the list
Johnsen et al. BMC Psychiatry  (2016) 16:60 Page 4 of 11
respectively, corresponding to being mildly ill. There
were no statistically significant differences between those
tested only at baseline and those with follow-up tests for
any of the clinical or demographic characteristics at
baseline presented in Table 1. Medication details are dis-
played in Table 2.
The distribution of CRP levels and overall cognitive per-
formance is displayed in Fig. 3. The mean CRP level and
overall cognitive performance were 4.6 (10.6) mg/L and
41.3 (7.1), respectively. The association between CRP level
and overall cognitive performance was not statistically sig-
nificant at follow-up (B = −0.045; Beta = −0.066;
p = 0.627). In sensitivity analyses that included also dur-
ation of treatment between baseline and follow-up, as well
as the mean defined daily dose of antipsychotics for the
latter 7 days before follow-up, the results remained un-
changed. In sensitivity analyses excluding the single pa-



























Fig. 1 Cognitive performance by functional domain. Notes: ♦ =mean t-score with bars representing plus/minus 1 standard deviation from
the mean
Fig. 2 Association between CRP level and overall cognitive performance at baseline. Notes: Scatter plot of overall cognitive performance versus
CRP level (N = 124). Pearson correlation r = −0.247, r2 = 0.061, p = 0.006. In sensitivity analyses excluding outliers with CRP >15 (N = 119): Pearson
correlation r = −0.346, r2 = 0.120, p = 0.000
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The results from the LGC models are presented in
Table 3 with mean and individual variation in baseline
level and change, and the relation between baseline level
and change. There was no statistically significant mean
increase in CRP, but considerable and statistically signifi-
cant individual variation in the change (Table 3). The re-
lation between baseline level and change was not
statistically significant.
Regarding cognition, there was a statistically signifi-
cant mean increase over time, however; with some
patients changing more than others indicated by statisti-
cally significant variance. For this variable it was found a
negative relationship between baseline score and degree
of change, which indicates stronger rate of change for
patients with lower baseline scores. Figure 4 illustrates
this with mean change over a four week period and
changes for patients with lower (−1 SD) and higher (+1 SD)
baseline scores.
The results from the final model consisting of two
growth processes with level and change in CRP and
overall cognition showed that baseline level in CRP could
predict changes in overall cognition (b = 0.04, p = 0.000),
after accounting for the covariate variables. Changes in
overall cognition were not related to changes in CRP
(b = −0.02, p = 0.764). The covariate variables showed
smokers to have less increase over time than non-
smokers (b = −0.18, p = 0.001) and that baseline CRP
level was moderated by the CVD risk baseline level
(interaction term: b = −0.06, p = 0.041). The main effect
of CVD risk was not found to be statistically significant
(b = 0.34, p = 0.072). This finding indicates a stronger
increase in overall cognition scores in patients with
higher baseline CRP levels, however, with stronger in-
creases in patients with lower degree of CVD risk
scores, and in non-smokers.
Discussion
The main finding of the present study was an inverse re-
lationship at baseline between serum levels of CRP and
overall cognitive performance, as well as for the
Table 2 Antipsychotic drug use at discharge/ 6 weeks
Risperidone Olanzapine Quetiapine Ziprasidone Aripiprazole
N = 14 N = 21 N = 14 N = 10 N = 1
Mean (SD/ range) Mean (SD/ range) Mean (SD/ range) Mean (SD/ range) Mean (SD/ range)
Mean dose (mg/ d) 3.3 (1.2/2.0–6.0) 16.6 (4.7/10.0–25.0) 480.4 (218.9/175.0–800.0) 82.0 (38.2/20.0–160.0) 5.0 (-)
Serum level (nm/ L)a 58.5 (33.3/ 27.0–147.0) 115.5 (70.3/47.0–302.0) 546.8 (585.3/ 62.0–1817.0) 88.6 (89.3/ 13.0–323.0) 141 (-)
N number of patients, SD standard deviation, mg/d milligrams per day, nm/L nanomoles per litre. There was missing medication data on 1 patient and 1 patient
had discontinued the antipsychotic medication
aReference ranges: Risperidone 30–120; Olanzapine 30–200; Quetiapine 100–800; Ziprasidone 30–200; Aripiprazole 200–1300
Fig. 3 Association between CRP level and overall cognitive performance at follow-up. Notes: Scatter plot of overall cognitive performance versus
CRP level (N = 62). Pearson correlation r = 0.007, r2 = 0.000, p = 0.958. In sensitivity analyses excluding outliers with CRP >15 (N = 60): Pearson correlation
r = 0.005, r2 = 0.000, p = 0.972
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subdomains Delayed memory and Attention, in a clinic-
ally relevant sample tested in the acute phase of psych-
osis. The association was particularly strong for the
subgroup with a diagnosis of schizophrenia. At follow-
up, which in time correspond to the end of the acute
phase, the association was no longer present. The find-
ing was restricted to cognitive performance, as none of
the other psychometric parameters tested were associ-
ated with the CRP level. The CRP level at baseline pre-
dicted the overall cognitive change.
Our results are consistent with those of Dickerson et
al. [28], who reported an inverse relationship between
CRP levels and cognitive performance but no association
towards other measures of psychopathology. Our study
adds new knowledge by including a consecutive sample
of patients acutely admitted for psychosis, with measure-
ments both at hospital admission and at discharge or
after maximally 6 weeks, thus giving the possibility to
analyze the data also with regard to longitudinal
changes. We argue that this period of time reflects the
phase of treatment with the most severe symptoms, sup-
ported by the decrease of the CGI-S scores from mark-
edly ill at baseline to mildly affected at follow-up.
Interestingly, the negative association between CRP
levels and overall cognitive performance was present
only at baseline. Since the sample at follow-up was
smaller than at baseline, the lack of statistically signifi-
cant difference at follow-up could be due to insufficient
statistical power. However, the correlation was reduced
substantially at follow-up, approaching zero, which
makes the lack of association unlikely to be a sample
size problem. Another possibility might be that the attri-
tion was not at random, giving rise to selection bias at
follow-up compared to the sample at baseline. This
seems unlikely, however, as attrition was not related to
any baseline characteristics. Finally, cognitive dysfunc-
tion might theoretically be associated with positive
symptoms of psychosis, and the positive symptoms
could accordingly confound the association between
CRP and cognitive performance, which could also ex-
plain why the association between CRP and cognitive
performance disappeared in remission. A sensitivity ana-
lysis was therefore undertaken to adjust for the potential
contribution from positive symptoms, but the results
remained unchanged, which is also in line with the find-
ing of a meta-analysis on the subject [65]. Taken
Table 3 Level and change results for CRP level and overall cognition based on latent growth curve models
Baseline (I) Change (S) Relation I,S
Mean Variance Mean Variance Cov r
CRP level 2.76*** 9.70 0.98 26.52 −1.33 −.08
Overall cognition 37.92*** 60.83 0.95*** 3.66 −5.53 −.37**
The model describes mean level and individual variations in baseline and change over time. The relation between intercept (I) and slope (S) describes the relation
between baseline level and rate of change (covariances and correlations). Cov covariance, r correlation coefficient






















Fig. 4 Model estimated cognitive change during follow-up. Notes: The figure shows mean change and change based on ± 1 SD baseline level.
Patients with lower cognitive scores had a higher rate of change. SD = standard deviation
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together, the inverse association between CRP and cog-
nition may accordingly be interpreted as at least partly
state dependent.
In our study, there was no association between CRP or
any of the clinical variables, which is not entirely in line
with the findings in the meta-analysis by Fernandes et al.
[27], who found an association between CRP and posi-
tive but not negative symptoms. The meta-analysis was
based on about 2,000 schizophrenia subjects and healthy
controls, and the apparent lack of an association in our
much smaller sample may be related to insufficient stat-
istical power. Our results are, however, in correspond-
ence with the Dickerson et al. [28] study finding no
association between CRP and any psychiatric symptoms.
The mean overall cognitive t-score increased significantly
between baseline and follow-up, and although the mean
CRP levels were almost identical at the assessment points,
the distribution changed substantially towards the cognitive
t-scores. Furthermore, the baseline CRP level was found to
predict change of cognitive performance. Hypotheses
regarding the biological substrate mediating the
inflammation-related effects on cognition can only be
speculative. There is however phase-specific fluctuations re-
ported for both myelin integrity and glutamate levels in
schizophrenia [66–70]. Considerable cross-talk has been
suggested between immuno-inflammatory processes, mye-
lin, and glutamate in schizophrenia, as recently reviewed by
Kroken et al. [21]. CRP is known to activate complement,
and the complement system have demonstrated different
and somewhat paradoxical effects in the central nervous
system (CNS) [71–73]. Some of these effects could be rele-
vant to neurodegeneration and inflammation in several
brain disorders including Alzheimer’s disease [72]. Inflam-
matory processes may also decrease the blood–brain-bar-
rier integrity, leaving the CNS more vulnerable to
complement protein infiltration from the periphery [74].
The present study also supplements the findings of
Dickerson et al. [28], as more than half the sample was
antipsychotic drug naïve, which could be used as a proxy
for early stage psychosis. The sub-analyses in the drug-
naïve patients revealed similar findings to those of the
total sample, with almost identical B and Beta values.
The non-significant p-value is probably related to insuf-
ficient statistical power in the small sample of drug naïve
patients. This interpretation is further supported by the
fact that entering medication status into the regression
did not change the association between CRP and cogni-
tion, which might indicate that the association between
CRP levels and cognition was not a result of longstand-
ing psychosis or medication (adverse) effects.
The cognitive deficits in schizophrenia are generally
considered to be stable over time [75, 76]. At odds with
this, we have previously reported an overall cognitive
performance improvement across time that was
considered clinically significant, and with some differen-
tial cognitive effectiveness among different second gen-
eration antipsychotics when data from the whole follow-
up period was analyzed [29]. In the present study, all but
one patient used antipsychotics at follow-up. It cannot
be ruled out that the significant cognitive improvement
observed also in the acute phase is antipsychotic drug-
related, but due to the lack of a placebo group no firm
conclusions can be drawn. It should be noted that anti-
inflammatory effects of antipsychotic drugs have been
reported in several studies [77, 78], providing a putative
link to any cognitive enhancement mediated by the
drugs in the present study.
We found significant inverse associations between
CRP levels and Delayed memory, and Attention subdo-
mains, respectively, whereas no significant associations
were present for the other subdomains. Aas et al. [79]
found overall cognitive impairment present already in
first episode psychosis patients with the largest effect
sizes for verbal memory, executive function, and general
IQ. Correspondingly, a global impairment was found
across all the subdomains in our sample, the Attention
subdomain had the lowest t-score, followed closely by
the Immediate memory and Delayed memory subdo-
mains. Seeking reasons for the associations with CRP
levels being present only in some of the subdomains is
outside the scope of this study. It is nevertheless an in-
teresting observation that the inverse association is
present in the subdomains showing the most pro-
nounced impairments which might indicate a greater
vulnerability to inflammation-related processes com-
pared to other subdomains of cognition.
Some limitations to the study should be mentioned.
Minor elevations in the CRP levels are associated with
numerous conditions and although we adjusted for sev-
eral potential confounders we may have missed other
unknown or hidden confounders between CRP levels
and cognitive performance. However, most of the condi-
tions associated with minimal CRP elevations do not
have an apparent relationship towards cognitive func-
tion, making them less likely to confound the results
presented here. As already discussed, the attrition rate
was substantial, and selection bias cannot be ruled out,
although attrition was not related to any baseline char-
acteristics. We used only CRP as a measure of inflamma-
tion, and clearly a broader display of inflammatory
markers would have added further strength to the study.
Finally, although the association found for the primary
outcome was highly statistically significant, the explained
variance was only modest.
Conclusions
Despite the limitations mentioned, the data support an
inflammatory component to the cognitive impairment in
Johnsen et al. BMC Psychiatry  (2016) 16:60 Page 8 of 11
schizophrenia and related psychoses, which may be at
least partly state dependent. Several anti-inflammatory
agents have shown promising results as add-ons to anti-
psychotic drug treatment in schizophrenia [80, 81]. Future
studies should prospectively and repeatedly examine lon-
gitudinal changes in CRP and other markers of inflamma-
tion, and their association with cognitive performance. If
our results are replicated, anti-inflammatory drugs may be
especially beneficial in the acute phase of psychosis for
cognitive enhancement.
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Abstract
Objective: Inverse relationships between the C-reactive protein (CRP) levels and cognitive
performance in acute psychosis have been demonstrated. We aimed to investigate how the
serum level and initial change of CRP in acutely admitted patients with psychosis was
correlated with cognitive performance during a 6-months follow-up period. Methods: The
study is part of a pragmatic, randomised trial comparing four different second-generation
antipsychotic drugs, and consists of 208 acute phase patients recruited at admittance for
psychosis. This study reports data for all groups collectively, and does not compare treatment
groups. Measurements of CRP and cognitive performance were conducted at baseline (T1)
and after 4 weeks on average after inclusion (T2). Cognition was also assessed after 3 months
(T3) and 6 months (T4) of follow-up. Results: Global cognition improved during the follow-
up period of 6 months, especially in the T1–T2 interval. The different cognitive subdomains
showed different time-dependent profiles of improvement, with memory and attention
improving significantly also in the later phases. Reduction of the CRP level during the initial
follow-up interval (T1–T2) was associated with increased overall cognitive performance in
the T2–T4 interval, but not in the T1–T2 interval. For the cognitive subdomains, we found
an inverse association between change in CRP level and verbal abilities (T2–T4 interval), and
attention (T2–T3 interval). Conclusion: These findings indicate that initial changes in the
serum level of CRP in the acute phase of psychosis may predict cognitive function in later
phases of the disease.
Trial registration
ClinicalTrials.gov ID; URL: http://www.clinicaltrials.gov/:NCT00932529
Significant outcomes
∙ Global cognition and several cognitive subdomains continued to improve beyond the
initial phase of acute psychosis treatment and into the later phase of follow-up.
∙ Reduction of the C-reactive protein (CRP) level in the initial acute phase was associated
with delayed improvement of global cognition. Inverse associations between CRP levels
and cognitive subdomains were found for learning, verbal abilities, and attention.
Limitations
∙ There was considerable attrition in the study during follow-up.
∙ CRP was the only inflammatory marker measured in the study.
Introduction
Cognitive dysfunctions are core features of schizophrenia that detrimentally affect func-
tional outcome (1–3). The neurobiological disturbances involved in cognitive dysfunctions
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immunological processes, including low-grade inflammatory
responses, have been suggested as possible mechanisms (4).
Many studies have indicated that the cognitive impairments
seem to stabilise after the first episode of psychosis (5,6),
although there have also been some findings suggesting cogni-
tive improvements (7–10). The inconsistent literature might at
least in part be explained by differences in the patient samples,
the duration of follow-up, and the cognitive test batteries. Taken
together, recent findings indicate that cognitive dysfunction is
not always irreversible and can be dynamic, especially in the
acute phases (11,12). Importantly, current treatment options in
psychosis, including psychosocial interventions and anti-
psychotic medications, have few if any beneficial effects on
cognitive performance (4,13–17). Thus, this central area of
dysfunction in psychosis is in need of a better understanding
and novel treatment approaches.
Inflammation has been the focus of recent studies addressing
the pathophysiology of psychotic disorders. Immune abnorm-
alities in the blood, cerebrospinal fluid, and central nervous
system, including immune cell numbers, inflammatory markers,
and antibody titers, have been demonstrated in schizophrenia
(18–23). There is increasing evidence for underlying inflam-
matory mechanisms relevant to cognitive functioning (4,24–26).
Indeed, neuroinflammation with white matter pathology has
been demonstrated in the early stages of psychosis (27), and it
has been suggested that these changes can lead to both structural
and functional dysconnectivity and cognitive dysfunction (21).
Low-grade elevation of the CRP, a well characterised and stan-
dardised marker of inflammation (28), has been found in some
studies in schizophrenia (29–35). An inverse association
between the serum levels of CRP and cognitive function has
been reported (18,36,37). However, these studies are pre-
dominantly cross-sectional and include patients in the chronic
phase. This might restrict the generalisability of the results, and
longitudinal studies with repeated cognitive assessments are
scarce.
We have recently shown an inverse association between the
serum level of CRP and cognitive performance in the acute phase
of psychosis (11). What remains unresolved, however, is whether
the levels and change of CRP in the initial phase of acute psy-
chosis influence cognition in later phases. The main aim of this
study was therefore to investigate how the CRP level in the first
acute phase of psychosis correlates with cognitive function during
a 6 months follow-up.
Material and methods
The study is part of a pragmatic, randomised trial comparing four
different second-generation antipsychotics in the treatment of
psychosis (Fig. 1). Importantly this study reports data for all
treatment groups collectively, and does not compare treatment
groups. We have previously published cross-sectional compar-
isons of treatment groups, and no differences were found (11).
The main objective of the present study was to investigate overall
associations between longitudinal changes in CRP and cognition
in the whole group. The clinical sample and methods have been
described in detail elsewhere (38).
Clinical sample
The sample consists of 208 consecutive, acute phase patients
recruited at admittance for psychosis, who underwent CRP
measurements and cognitive assessment. The project was
designed and approved by the Ethics committee with two phases:
The first was the quality assurance phase from admission to
discharge or 6 weeks at the latest, and was approved by the
Ethics Committee without the requirement of informed consent
as this phase included only elements of best clinical practice.
At admission all psychotic patients admitted to the hospital for
symptoms of acute psychosis were consecutively included, if they
were to use the hospital’s standard antipsychotic medication
regimen, and could cooperate with clinical assessments of con-
dition. This phase should assure that psychosis patients were
offered best-quality guideline-concordant treatment for psychosis.
The second phase (research phase) was based on informed con-
sent provided at discharge or after 6 weeks at the latest. This
included invitation to visits and tests at 3, 6, 12, and 24 months
after admission. In this part of the project there were procedures
beyond usual clinical standard, such as collections of data for
use in psychiatric basic research within genetics and brain
functioning.
The recruitment period was from March 2004 until February
2009 at Haukeland University Hospital, Bergen, Norway, with a
catchment population of about 400 000. The study was approved
by the Regional Committee for Medical Research Ethics, and by
the Norwegian Social Science Data Services. The study was
publicly funded and did not receive any financial or other support
from the pharmaceutical industry.
All adult patients were eligible for participation if they were
acutely admitted to the emergency ward for symptoms of active
psychosis, as determined by a score of ≥4 on one or more on the
items Delusions, Hallucinatory behaviour, Grandiosity, Suspi-
ciousness/persecution, or Unusual thought content in the Positive
and Negative Syndrome Scale (PANSS) (39) and were candidates
for oral antipsychotic drug therapy. All eligible patients met the
International Statistical Classification of Diseases and Related
Health Problems (ICD)-10 diagnostic criteria (http://apps.who.
int/classifications/icd10/browse/2010/en) for schizophrenia, schi-
zoaffective disorder, acute and transient psychotic disorder,
delusional disorder, drug-induced psychosis, major depressive
disorder with psychotic features, bipolar disorder except manic
psychosis. Manic psychosis was excluded based on a priori
expectation that these patients would not be able to cooperate
with the assessments in the acute phase.
Figure 1. Estimated mean level and change in global cognitive score over time, with
standard deviations to display individual variation (N= 181).
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Patients were excluded from the study if they were unable to
use oral antipsychotics, were suffering from manic psychosis or,
for other behavioural or mental reasons related to the state of
illness, were unable to cooperate with assessments, did not
understand spoken Norwegian, were candidates for electro-
convulsive therapy, or were medicated with clozapine on admit-
tance. Patients with drug-induced psychoses were included only
when the condition did not resolve within a few days and when
antipsychotic drug therapy was indicated.
The patients were assessed at baseline (T1: N= 208 with data
on CRP level and/or cognition), at the first follow-up (on average
after 4 weeks; T2: N= 103), at the second follow-up after
3 months (T3: N= 43), and at the third follow-up after 6 months
(T4: N= 35). This period corresponds to the treatment of the
acute phase during which the largest reduction of psychotic
symptoms is seen, and treatment response is expected in the
majority of patients (40).
Clinical and biochemical assessments
Eligible patients underwent the PANSS structured clinical inter-
view at baseline, before inclusion. All tests were performed by
personnel independent of the clinical departments, who were
trained and with inter-rater reliability training. Intra-class cor-
relation coefficients were calculated based on inter-rater assess-
ments and showed high inter-rater reliability (0.92). Furthermore,
the Calgary Depression Scale for Schizophrenia (41), and the
Clinical Drug and Alcohol Use Scales (42) were used, and the
patients were rated according to the Clinical Global Impression-
Severity of Illness Scale (43), and the Global Assessment of
Functioning-Split Version, Functions Scale (44). Illicit drug use
data was based only on information from the participant.
For analysis of CRP, a blood sample was collected from the
patients in the fasting state between 08:00 and 10:00 h in the
morning at baseline (T1) and after 4 weeks follow-up (T2).
The laboratory changed the routine CRP analysis method in Jan-
uary 2005, and hence only data obtained after this revision is used in
the present work. The CRP level was measured by the Tina-quant
C-reactive Protein (Latex) method from Roche Modular P®
(Mannheim, Germany), which measures CRP levels >1mg/l.
Cognitive assessment
Cognitive assessments were conducted at baseline (T1)
and follow-up (T2, T3, and T4). A brief neuropsychological
screening instrument with alternative forms; the Repeatable
Battery for the Assessment of Neuropsychological Status
(RBANS), was used to minimise potential practice effects (45–
47), since longitudinal studies on cognitive functioning usually
do not sufficiently address the issue of practice effects (48,49).
The RBANS has previously shown to have good reliability and
validity in psychosis (47). To increase clinical validity, a more
comprehensive cognitive battery, but with the same cognitive
subdomains, was administered at T3 (Table 1). In a pre-
liminary analysis, a satisfactory relationship between the
RBANS/short battery and equivalent domains from the long
battery/more comprehensive neuropsychological battery
3 months later emerged, even despite of symptom-level dif-
ferences at the two time points (50). The five cognitive
domains were the same as for the RBANS: Language;
Visuospatial/constructional; Immediate memory; Delayed
memory; and Attention. We have used the already set
domains from the RBANS, which does not include executive
functioning. We do argue, however, that both Trails B and
Stroop do depend as much on attentional resources, as
executive functioning making it correct to group them together
with the Attention domain. If we had an executive domain we
would have grouped in this domain also. The policy of
grouping test with several domains when they do capture
several cognitive processes is what we consider the most
transparent way of taking the complexity into account. The
grouping of WAIS III digit span with both Attention and
Learning was done for the same reason. In addition, in the
before mentioned preliminary analysis, this method of grouping
Table 1. Neuropsychological assessment by cognitive subdomain and time
Cognitive
subdomain T1 (baseline) T2 (4 weeks*) T3 (3 months) T4 (6 months)
Verbal
abilities














Attention RBANS A attention RBANS B attention WAIS-III digit span
Digit vigilance test (time)CalCAP CPT (choice
reaction time/sequential reaction time)
Trail making test B
Stroop colour/word conflict (time)
WAIS-III digit span
CalCAP CPT (choice reaction time/
sequential reaction time)
Stroop colour/word conflict (time)
















CalCAP CPT, California Computerized Assessment Package-Continuous Performance Test; COWAT, Controlled Oral Word Association Test; CVLT, California Verbal Learning Test; RBANS,
Repeatable Battery for the Assessment of Neuropsychological Status; ROCF, Rey Osterrieth Complex Figure Test; WAIS-III, Wechsler Adult Intelligence Scale; WMS-R, Wechsler Memory Scale-
Revised.
*Mean follow-up time at T2 was 4.1 weeks after baseline.
38 Fathian et al.
https://www.cambridge.org/core/terms. https://doi.org/10.1017/neu.2018.25
Downloaded from https://www.cambridge.org/core. IP address: 109.189.169.154, on 03 Jul 2019 at 11:11:33, subject to the Cambridge Core terms of use, available at
the tests was the one that obtained a satisfactory relationship
with the RBANS (50). Raw scores for the neuropsychological
variables were converted to t-scores using the best available
norms from corresponding manuals (when available) or pub-
lished papers. The final summary score based on the mean t-
scores across the five cognitive domains defined the overall
cognitive function t-score. Neuropsychological assessment by
cognitive domain and time are shown in Table 1.
Statistical analyses
Descriptive statistics (mean, standard deviation, frequency) and
independent sample-t-test were analysed with SPSS version 24.0.
The program Mplus 8 (51) was used to analyse the level and
change in variables with latent growth curve and time contrast
models (52). The standard linear change assumption was tested
based on the goodness of fit measures, residual results, and plots
of the observed and estimated change model were used to decide
the change pattern. If this assumption was not met, piecewise
growth was explored. If the model indicated one piece based on
two measurements only, this part is a difference score model (53).
Some residuals had to be set as constant to fit such a model. The
models were evaluated based on their goodness of fit measures, as
follows: threshold values in comparative fit index and Tucker–
Lewis index beyond 0.95; root mean error of approximation
(RMSEA)< 0.05 as close fit, RMSEA <0.08 as fair fit, and RMSEA
<0.10 as a mediocre fit (52). Model fit measures were presented
for unconditional level and change models, but not for prediction
models, as these models solely are predictions with statistical
significant and non-significant relations and not structural
models. The estimator was set to maximum likelihood with
robust standard errors (MLR) to account for non-normality in
data (54). The full information maximisation likelihood (FIML)
method uses all available data under the assumption that missing
data are random (‘Missing at Random’) (51,54). Thus, the level
and change results are estimated and not observed values based
on all observations. After analysing the variables separately, level
and change in CRP were related to levels and changes in neu-
rocognitive scales. A sensitivity analysis was performed for CRP
levels <10mg/l.
Finally, we controlled for confounders, known to have impact
on both CRP level and cognition, as metabolic syndrome,
smoking, being antipsychotic medication-naive, illicit drug use,
and educational level (11).
Results
The study included 208 patients with data in one or more of the
outcome variables. At baseline, there were CRP measurement for
158 patients and cognitive assessments for 169 patients and a total
of 123 patients had both measurements. In total, 181 patients had
observations on cognitive performance and 169 on CRP at any
time point. The demographic and clinical characteristics are
shown in Table 2. The patients that were tested only at baseline
were not statistically different from those with follow-up data for
the clinical or demographic characteristics at baseline, with the
exception of a higher PANSS negative subscale score in patients
with baseline test only compared to those with two or more visits
[independent samples t-test: p= 0.034; mean difference 2.2
points; 95% confidence interval (CI): 0.2–4.2], and fewer years of
education (independent samples t-test: p= 0.027; mean differ-
ence, 0.8 years; 95% CI: 0.10–0.6).
Levels and changes in cognitive performance
The mean and individual levels and changes in cognitive sub-
domains are presented in Table 3. The mean level of global
cognitive performance increased over time in a non-linear man-
ner, being most pronounced in the T1–T2 interval (Fig. 1). The
figure also shows more individual change variation in the T1–T2
interval than in the later intervals. Statistically significant
improvements over time were also found for verbal abilities,
Table 2. Baseline demographics and clinical characteristics (N= 208)
Characteristics N %
Male 143 68.8
Antipsychotic drug naive 92 44.2
Alcohol abuse last 6 months 22 10.6
Illicit drug use last 6 months 139 66.8
Current tobacco smoking 103 49.5
Diagnosis*
Schiz and related 106 53.2
Drug-induced 28 14.1
Affective 23 11.6
Acute psychosis 17 8.5
Other 25 12.5
Mean SD Range
Age 33.5 13.1 17–73
Body mass index 23.7 4.8 15.8–42.6
Years of education 12.5 2.8 8.0–22.0
PANSS total 74.1 13.2 44–111
PANSS positive 19.9 4.4 11–32
PANSS negative 19.6 7.4 7–39
PANSS general 34.6 6.7 20–56
CDSS 6.6 5.2 0–23
GAF-F 30.7 6.0 2–62
CGI 5.2 0.6 4–6
RBANS 38.3 7.7 20.2–58.8
CRP 4.0 8.3 0–89
N, number of patients; Antipsychotic drug naive, no life-time exposure to antipsychotic
drugs before index admission; Abuse, abuse or dependence according to the Clinical Drug
and Alcohol Use Scales (CDUS/CAUS), patients with no illicit drug use could be included in
the category alcohol use last 6 months; Schz and related, schizophrenia and related dis-
orders: Schizophrenia, schizoaffective disorder, acute polymorphic psychotic disorder with
symptoms of schizophrenia, acute schizophrenia-like psychotic disorder, delusional dis-
order; Acute psychosis, acute psychosis other than those categorised under Schz and
related; Affective, bipolar and unipolar depression; Other, miscellaneous psychotic dis-
orders.
CDSS, the Calgary Depression Scale for Schizophrenia; CGI, the Clinical Global Impression,
severity of illness scale; CRP, C-reactive protein (mg/l); GAF-F, the Global Assessment of
Functioning, split version, Functions scale; PANSS, the Positive and Negative Syndrome
Scale; RBANS, the Repeatable Battery for the Assessment of Neuropsychological Status.
All diagnoses are according to ICD-10;
*Patients with missing diagnoses are not included in the list. According to the naturalistic
design, patients were included on the basis of the presence of active psychosis as deter-
mined by the PANSS, and not based on diagnosis.
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learning and attention in the T1–T2 interval, and for memory and
attention in the T2–T4 interval, respectively. Individual differ-
ences in change (standard deviation) were also present. Some
patients improved their performance, whereas others showed
decline. The goodness of fit measures showed close fit between
model and data for global cognitive performance, verbal abilities
and learning scales, while the other three scales were based on
saturated models and thereby giving no fit measures (please see
Supplementary Table 1).
The relationship between levels and changes in CRP
and cognition
The mean change in CRP from T1 to T2 was not statistically
significant (0.52mg/l/ month, p= 0.652, baseline mean level:
3.99mg/l, SD = 8.32). However, the individual variation in
change was statistically significant (SD = 12.13, p= 0.031). In the
total sample, a reduction in the CRP level from T1 to T2 was
associated with an increase in global cognitive performance in the
T2–T4 interval, whereas no such association was found between
CRP and cognition during the T1–T2 interval (Table 4). Patients
with most reduction in CRP also were the patients with most
improvement in global cognitive performance, illustrated with a
steeper increase in their performance, compared to those with a
smaller reduction or an increase in CRP (Fig. 2).
For the cognitive subdomains, we observed a statistically sig-
nificant association between reduction of the CRP level and
increase in verbal abilities for the T2–T4 interval and in attention
for the T2–T3 interval (Table 4).
For patients with CRP <10mg/l (N= 191), the results
remained unchanged regarding the association between changes
in global cognitive performance (T2–T4), verbal abilities (T2–T4),
and attention (T2–T3), and CRP level changes. However, we also
found additional statistically significant associations in this sub-
sample compared to the total sample (Table 4).
A separate model for the sub-sample of patients diagnosed
within the schizophrenia spectrum showed that change in CRP
level did not predict T2–T4 change in the global cognitive per-
formance as was found in the total sample (b= − 0.01, p= 0.208).
Two new statistically significant associations were found between
change in CRP level and attention in the T1–T2 interval (b= 0.12,
p= 0.045) and in the T3–T4 interval (b= 0.03, p= 0.026).
Finally, the models were adjusted for the covariates metabolic
syndrome, smoking, being medication naïve, illicit drug use, and
the educational level. The association between baseline CRP level
and global cognitive performance for the whole follow-up
remained essentially unchanged. Baseline CRP level and visuos-
patial performance in the T3–T4 interval was no longer statisti-
cally significant (p= 0.120), whereas a statistically significant
association was found between CRP baseline level and this sub-
domain in the T1–T2 interval (b= 0.66, p= 0.018). CRP level
change and verbal abilities in the T2–T4 interval was no longer
statistically significant associated (p= 0.067), while such an
association was found in the T1–T2 interval (b= − 0.09,
p= 0.039). Additional statistically significant associations were
found between CRP baseline level and attention in the T3–T4
interval (b= 0.31, p< 0.001), and CRP level change and attention
in the T1–T2 interval (b= 0.12, p= 0.045), and in the T3–T4
(b= 0.03, p= 0.026), respectively.
A separate model for the sub-sample of patients diagnosed
within the schizophrenia spectrum showed some differences.
Change in CRP did not predict T2–T4 change in the global score
as it did in the total sample (b= − 0.01, p= 0.208), whereas
change in CRP was found to be associated with change in
attention for the T1–T2 (b= 0.12, p= 0.045) and T3–T4 (b= 0.03,
p= 0.026) intervals, respectively.
In the schizophrenia group, the inclusion of covariates showed
that higher CRP baseline level was related to lower baseline level
in global cognitive performance (b= − 0.26, p= 0.036). CRP
baseline level was found to be associated with verbal abilities in
the T1–T2 interval (b= 0.64, p= 0.016). In addition, CRP level
change was found to be associated with verbal abilities in
(b= − 0.09, p= 0.024) and learning in the T1–T2 interval
(b= −0.04, p= 0.009). The model with the attention outcome
variable did not converge, even after increasing the number of
iterations.
Discussion
The main finding of the present study was that the global cog-
nitive performance continued to improve from the initial phase
(baseline to 4 weeks) of acute psychosis to the later phase (4 weeks
to 6 months), and was predicted by the reduction of the CRP level
as observed during the initial phase (baseline to 4 weeks) of the
Table 3. Levels and changes in global cognition and cognitive subdomains over time
T1 Level (I) Change T1–T2 (S1) Change T2–T4 or change T2–T3 (S2)* Change T3–T4 (S3)*
Scale Mean SD p Mean p SD p Mean p SD p Mean p SD p
Global performance 38.3 7.6 0.000 2.9 0.000 4.9 0.000 1.4 0.000 1.1 0.003
Verbal abilities 40.1 8.4 0.000 6.0 0.000 6.8 0.000 0.2 0.643 2.0 0.002
Visuospatial abilities* 47.3 12.1 0.000 1.4 0.148 10.1 0.000 − 0.7 0.295 5.1 0.000 2.1 0.000 3.2 .004
Learning 35.8 8.1 0.000 2.9 0.000 1.7 0.078 − 0.3 0.315 1.9 0.000
Memory* 38.1 12.1 0.000 1.2 0.326 11.3 0.000 2.8 .000 4.8 .000 3.0 .000 2.3 .000
Attention* 29.7 9.0 0.000 3.5 0.000 7.4 0.000 4.2 .000 4.0 .000 0.4 .167 2.1 .000
The time unit for change is months. T1, baseline; T2, 4 weeks; T3, 3 months; T4, 6 months.
S1: change from T1–T2; S2: change from T2–T4 if supported by data; and S3: change T3–T4. Change in the T3–T4 interval was estimated if a linear change from T2–T4 was not supported. In
these models, S2 consists of the change between T2–T3.
Group mean and individual differences (standard deviation, SD) for both level and change are reported.
Statistical p-values are presented for individual differences at baseline level (T1 Level), and mean change and individual differences in change (standard deviation).
*Three change factors had to be estimated: S1: T1–T2; S2: T2–T3; and S3: T3–T4.
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treatment. Similar associations were found for several of the
cognitive subdomains. These findings might indicate a prolonged
effect of inflammatory processes on cognition after an acute
psychosis, stretching beyond the initial phase.
The stability of cognitive dysfunctions in patients with psy-
chosis has been debated for decades. Most studies have suggested
stability or decline in cognitive functioning (55–58). A study of
first-episode schizophrenia spectrum disorders and controls with
follow-up intervals of 1-year and 3-years showed that, although
patients performed worse than controls at any given time, the
cognitive performance of the patients improved in a similar way
as the controls in all domains, except for verbal and visual
memory, which showed greater improvement in controls (6).
Another longitudinal study demonstrated improvement of gen-
eral cognitive function, working memory, and verbal learning
after 12 weeks, but these changes were mediated by improve-
ments in both positive and negative symptoms (59).
There is substantial evidence that inflammatory processes are
involved in the cognitive performance in psychosis (23,60,61).
Oxidative stress and inflammation have been suggested to be
associated with specific aspects of cognitive functioning in first-
episode psychosis patients (62). Of particular interest, several
studies have shown a link between CRP and cognitive function
(25,29,37,63,64). CRP levels have been associated with cognitive
impairment in patients with schizophrenia (25,36). In one study,
abnormal CRP levels were correlated with poorer cognitive
Table 4. Baseline level and changes over time in cognitive performance predicted by baseline and change in C-reactive protein (CRP) level
Total sample Subsample (CRP <10 mg/l)
CRP level T1 CRP change T1–T2 CRP level T1 CRP change T1–T2
b β p b β p b Β p b β p
Global performance
T1 − 0.35 − 0.37 0.002 – – – − 0.70 − 0.17 0.059 – – –
T1–T2 0.13 0.21 0.455 − 0.01 − 0.03 0.748 0.95 0.34 0.013 − 0.02 − 0.04 0.573
T2–T4 0.08 0.54 0.025 − 0.02 − 0.18 0.004 − 0.07 − 0.12 0.684 − 0.02 − 0.14 0.026
Verbal abilities
T1 − 0.35 − 0.35 0.120 – – – − 0.75 − 0.17 0.095 – – –
T1–T2 0.13 0.17 0.610 − 0.06 − 0.10 0.124 1.11 0.30 0.082 − 0.07 − 0.09 0.103
T2–T4 0.11 0.39 0.197 − 0.04 − 0.23 0.003 0.17 0.15 0.600 − 0.03 − 0.14 0.039
Visuospatial abilities
T1 − 0.28 − 0.19 0.067 – – – − 0.49 − 0.07 0.434 – – –
T1–T2 0.56 0.44 0.059 0.04 0.05 0.724 0.94 0.16 0.146 0.05 0.05 0.684
T2–T3 − 0.31 − 0.48 0.111 − 0.05 − 0.11 0.416 − 0.96 − 0.34 0.048 − 0.06 − 0.11 0.311
T3–T4 0.16 0.40 0.022 0.01 0.02 0.699 0.53 0.29 0.043 0.01 0.02 0.663
Learning
T1 − 0.32 − 0.32 0.024 – – – − 0.47 − 0.10 0.337 – – –
T1–T2 − 0.01 − 0.04 0.916 − 0.02 − 0.17 0.198 0.54 0.44 0.008 − 0.02 − 0.10 0.112
T2–T4 − 0.09 − 0.37 0.200 0.01 0.06 0.512 − 0.58 − 0.54 0.041 0.01 0.05 0.360
Memory
T1 − 0.63 − 0.41 0.002 – – – − 1.30 − 0.10 0.000 – – –
T1–T2 0.25 0.18 0.288 − 0.06 − 0.06 0.501 0.62 0.44 0.144 − 0.06 − 0.05 0.488
T2–T3 0.06 0.10 0.673 0.05 0.13 0.142 0.23 0.15 0.300 0.05 0.10 0.143
T3–T4 − 0.15 − 0.50 0.260 − 0.02 − 0.11 0.074 − 0.22 − 0.30 0.222 − 0.02 − 0.10 0.080
Attention
T1 − 0.42 − 0.38 0.001 – – – − 1.06 − 0.21 0.002 – – –
T1–T2 0.50 0.54 0.191 0.10 0.16 0.096 1.75 0.43 0.001 0.06 0.07 0.304
T2–T3 − 0.12 − 0.26 0.903 − 0.08 − 0.24 0.003 − 0.43 − 0.19 0.225 − 0.06 − 0.14 0.047
T3–T4 − 0.06 − 0.21 0.684 0.03 0.17 0.070 0.63 0.56 0.003 0.02 0.11 0.040
The table presents results for all patients (i.e. total sample) and patients with CRP <10mg/l (i.e. subsample). The time unit for change is months.
Relations are given by unstandardised and standardised regression weights (b and β).
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functioning of general intellectual ability, abstract reasoning,
memory, working memory, semantic memory, learning abilities,
attention, mental flexibility, and processing speed (25). In
another, longitudinal study, CRP levels did not predict changes in
cognitive performance (65), but this study included chronic phase
patients with an average illness duration of 22.5 years, who are
likely to have a lesser potential for inflammation related cognitive
improvements.
Taken together, the present study supports a link between
inflammation and cognitive performance in schizophrenia. Our
study shows that early low-grade inflammation can predict cog-
nitive improvement in later phases. Some studies have suggested
that low-grade inflammation as indicated by elevated CRP levels
is related to cerebral microstructural disintegration, involving
frontal lobe executive functions (66). It has been suggested that
increased levels of CRP can increase blood–brain barrier per-
meability, which might lead to inflammatory-related cognitive
impairment (67). As neuroinflammation has been demonstrated
to be associated with white matter pathology (27), any psychosis-
related inflammation could, in principle, have a negative impact
on brain tissue components of relevance to cognition, and the
reversibility of such effects would likely include more slow
regenerative processes.
There are some limitations to this study. First, attrition was
substantial, but generally not related to any of the baseline
characteristics except a higher PANSS negative subscale score and
lower educational level in those patients tested only at baseline. As
negative symptoms have been found to correlate with cognitive
dysfunctions (12), those with the most pronounced cognitive
difficulties may have dropped out during follow-up.
It is, however, difficult to predict how any selective dropout
might have biased our results. Furthermore we used statistical
methods that reduce the effect of missing data (68), and give
improved statistical power and generalisability to the results, as all
information in the data set is taken into consideration, rather than
using the listwise deletion method that gives a net sample based
on intact data in all variables under the assumption of missing-
ness to be completely at random. However, the FIML method
does not rule out the possibility of missingness to be non-random.
The study included several models for different outcome variables
in the total sample and in the schizophrenia sub-sample. In
addition, several covariate variables were included in sensitivity
analyses. This strategy has implication for statistical power, which
has consequences particularly for small effects. Studies with larger
samples are needed to increase the validity of our findings.
Being exploratory, we did not adjust for multiple testing. The
high number of tests could theoretically result in statistical type I
error. However, we find it very unlikely that such a high number
of statistically significant findings could be the result of chance.
According to the naturalistic design, patients were included on
the basis of the presence of active psychosis as determined by the
PANSS, and not based on diagnosis. Hence all patients were
psychotic and in need of antipsychotic medication. The lack of
specific diagnosis for nine patients probably reflects that some
patients may have dropped out or been discharged before the
treating clinician were able to make a proper diagnostic evalua-
tion. This is clearly a limitation, but the direction of any influence
on our results is difficult to predict.
Moreover, CRP was the only inflammatory marker that was
measured, at baseline and the first follow-up (T2). Further mea-
surements during the follow-up period would have allowed for
analyses of associations between potential later changes in the
CRP level and cognitive performance. We are also aware of the
limitation that other factors potentially confounding the rela-
tionship between CRP and cognition might exist that we have not
accounted for, although many relevant factors were included in
the analyses. Finally, the cognitive test battery at the T3 follow-up
was more comprehensive but assessed the same cognitive
domains as the test battery at T1, T2, and T4. We have no reason
to suspect that this difference could have influenced the results.
We have shown that initial changes in the serum level of CRP
in the acute phase of psychosis may predict cognitive function in
later phases of the disease. These findings create an opportunity
for future RCT research efforts to develop more individualised
treatments with add-on anti-inflammatory agents (69). Some
efforts have already been made in this field of research, but the
results are mixed. A double-blind, randomised, placebo-con-
trolled, add-on study with Celecoxib, a cyclo-oxygenase-2 inhi-
bitor showed significant effect on the total PANSS score and the
cognition factor of PANSS scale in patients with schizophrenia
(70). N-acetyl cysteine significantly improved working memory
compared to placebo in patients with psychosis, however, these
preliminary data require replication (71). A double-blind, ran-
domised study with minocycline treatment was associated with
improvement in negative symptoms and executive functioning in
early phase schizophrenia (72), whereas another study with add-
on minocycline treatment showed improvement in negative
symptoms, but not in cognition (73). Aspirin given as add-on
treatment in another study reduced the total and positive PANSS
score, but did not affect cognitive function (74). Finally, omega-3
fatty acid (ethyl eicosapentaenoic acid) add-on treatment did not
affect cognition, positive or negative symptoms (75). Possible
explanations for the equivocal findings might at least in part be
related to small, unselected samples both with and without signs
of an increased inflammatory status, with predominantly chronic
phase psychosis, and with anti-inflammatory agents under
investigation typically of low anti-inflammatory potency (76).
Therefore, a more targeted approach might be to investigate more
potent anti-inflammatory agents, for example, corticosteroids, in
selected samples with signs of low-grade inflammation as deter-
mined by, for example, elevated CRP levels.
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